

CURRICULUM VITAE

Prof. **MICHELANGELO FIORENTINO**

Nato il **27 Ottobre 1967**

Cittadinanza: **Italiana**

- Email: michelangelo.fiorentino@unibo.it

Titoli accademici e certificazioni

- 1986, LICEO GINNASIO "L.GALVANI", BOLOGNA; DIPLOMA DI MATURITA' CLASSICA
- 1992, UNIVERSITA' DI BOLOGNA; LAUREA IN MEDICINA E CHIRURGIA (110/100 E LODE)
- 1992 UNIVERSITA' DI BOLOGNA; ABILITAZIONE ALL'ESERCIZIO DELLA PROFESSIONE DI MEDICO CHIRURGO
- 1993 ISCRIZIONE ALL'ALBO DELL'ORDINE DEI MEDICI E DEGLI ODONTOIATRI DELLA PROVINCIA DI BOLOGNA. TESS. N.12600
- 1996 UNIVERSITA' DI MODENA E REGGIO EMILIA; TITOLO DI DOTTORE DI RICERCA IN "BIOLOGIA GENERALE ED APPLICATA DEI TUMORI DELL'APPARATO DIGERENTE"
- 2000 UNIVERSITA' DI BOLOGNA; DIPLOMA DI SPECIALIZZAZIONE IN ONCOLOGIA A INDIRIZZO DIAGNOSTICO (70/70 E LODE) (ai sensi del DLgs 257/1991 DLgs 368/1999, durata anni 4)
- 2010-2017 HARVARD SCHOOL OF PUBLIC HEALTH; DEPARTMENT OF EPIDEMIOLOGY; ADJUNCT ASSISTANT PROFESSOR OF EPIDEMIOLOGY
- 2017-2028 T.CHAN HARVARD SCHOOL OF PUBLIC HEALTH; DEPARTMENT OF EPIDEMIOLOGY; ADJUNCT ASSOCIATE PROFESSOR OF EPIDEMIOLOGY
- 2017-2019 UNIVERSITA' DI BOLOGNA, PROFESSORE ASSOCIATO DI PATOLOGIA CLINICA (MEDS-02/B ex-MED/05; 06/A2)

- 2019- A OGGI UNIVERSITA' DI BOLOGNA, PROFESSORE ASSOCIATO DI ANATOMIA PATOLOGICA (MEDS-04/A ex-MED/08; 06/A4)
- 2016 UNIVERSITA' DEGLI STUDI DI BOLOGNA / REGIONE EMILIA-ROMAGNA; CERTIFICATO DI FORMAZIONE MANAGERIALE; CORSO DI ALTA FORMAZIONE CONTINUA E PERMANENTE PER LA DIREZIONE DELLE STRUTTURE SANITARIE COMPLESSE

Formazione

- 1994-1995 HARVARD MEDICAL SCHOOL; NEW ENGLAND DEACONESS HOSPITAL, BOSTON, MA U.S.A. RESEARCH FELLOW, DEPT.OF PATHOLOGY, LABORATORY OF MOLECULAR PATHOLOGY (PROF. M. LODA)

Possesso del requisito ASN (Abilitazione Scientifica Nazionale)

- *Settore concorsuale 06/A4 Anatomia Patologica I Fascia; I quadrimestre 2016-2018*
 - data di conseguimento 12/04/2017
 - data di scadenza: 12/04/2028

Attività di ricerca

Organizzazione, direzione e coordinamento di centri e/o gruppi di ricerca nazionali

- **2010-2012** ProgettoSA43FIOR "Impatto clinico-assistenziale delle analisi mutazionali dei geni KRAS, BRAF, EGFR e PIK3CA nel trattamento personalizzato dei pazienti oncologici con tumori solidi" AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI

Ruolo: Principal Investigator Finanziamento Euro 70.000

- **2011-2013** Progetto"Ottimizzazione metodologica dei tests molecolari per i geni HER2, KRAS, BRAF, EGFR, CKIT, nei pazienti con tumori solidi da sottoporre a terapie oncologiche personalizzate" REGIONE EMILIA-ROMAGNA, PROGETTI UNIVERSITA'-REGIONE

Ruolo: Principal Investigator Finanziamento Euro 240.900

- **2020** ProgettoOrganizzazione e gestione dei percorsi formativi di re-training rivolti agli operatori cito-istologici per la promozione della qualità dei programmi di screening. REGIONE EMILIA-ROMAGNA, PIANO REGIONALE DELLA PREVENZIONE

Ruolo: Principal Investigator Finanziamento Euro 12.000

- **2021-2022** Progetto “Controllo di qualità istologico e immunoistochimico delle lesioni serrate del colon e dei tumori coloretali con instabilità micro satellitare. REGIONE EMILIA-ROMAGNA, PIANO REGIONALE DELLA PREVENZIONE

Ruolo: Principal Investigator Finanziamento Euro 16.000

- **2022-2024** Progetto “Patho-epidemiological association of male sex, prostate cancer and lethality from Sars Cov-2” REGIONE EMILIA-ROMAGNA BANDO RICERCA FINALIZZATA BOTTOM UP

Ruolo: Principal Investigator Finanziamento Euro 184.000

Organizzazione, direzione e coordinamento di centri e/o gruppi di ricerca internazionali

- **2008 DANA-FARBER CANCER INSTITUTE, BOSTON, MA, U.S.A. CENTER FOR MOLECULAR ONCOLOGIC PATHOLOGY**

Ruolo: Associate Director

Partecipazione a centri e/o gruppi di ricerca nazionali

- **2013-2015** Collaboratore al progetto “Molecular classification of hepatocellular carcinoma to select the more appropriate surgical treatment: liver transplantation or liver resection” REGIONE EMILIA-ROMAGNA PROGETTI UNIVERSITA’-REGIONE. Finanziamento **Euro 72.640**
- **2014-2016** Collaboratore al progetto “¹⁸F-FACBC PET/CT for staging high risk prostate cancer” REGIONE EMILIA-ROMAGNA PROGETTI UNIVERSITA’-REGIONE. Finanziamento **Euro 27.368**
- **2013-2016** Collaboratore al progetto “Use of biomarkers and gene expression profiles to identify cancer patients with different prognosis and sensitivity to molecular targeted agents” REGIONE EMILIA-ROMAGNA PROGETTI UNIVERSITA’-REGIONE. Finanziamento **Euro 33.000**
- **2016** Collaboratore al progetto “Caratterizzazione molecolare avanzata di tumori solidi candidate al trattamento con terapie mirate innovative”. BANDO FONDAZIONE DEL MONTE DI BOLOGNA E RAVENNA. **Finanziamento Euro 33.000**
- **2021-2024** Collaboratore al progetto “Improving prostate cancer prognostication through an integrated approach”. Bando AIRC Investigator Grant 2020. **Finanziamento Euro 28.000**

Partecipazione a centri e/o gruppi di ricerca internazionali

- **2016-2018** Collaboratore al progetto “PROMORT, prostate cancer mortality”. University of Orebro, Karolinska Institutet, Svezia **Finanziamento Euro 86.000**

Partecipazione a comitati editoriali di riviste

- Membro dell'Editorial Board della rivista **ClinicalCancerResearch**
- Membro dell'Editorial Board della rivista **MolecularCancerResearch**

Conseguimento di premi e riconoscimenti nazionali

- 1995 Vincitore di una Borsa di Studio Triennale AIRC della Associazione Italiana per la Ricerca sul Cancro AIRC

Conseguimento di premi e riconoscimenti internazionali

- 2000 Vincitore di un Pezcoller Young Investigator Award, 91° Meeting of the American Association for Cancer Research. San Francisco , U.S.A.

Partecipazione in qualità di relatore a congressi e convegni di interesse nazionale (ultimi 5 anni)

- Relatore su invito con la relazione "Carcinoma prostatico Grade group I. Sempre innocente?" al XXIX Congresso della Società Italiana di Urologia Oncologica (SIURO), Bologna 11-13Aprile 2019
- Relatore su invito con la relazione dal titolo "La diagnosi molecolare del carcinoma coloretale"al Simposio "Come curare oggi il cancro del colon destro" Firenze, 21 Febbraio 2020.
- Relatore su invito con la relazione "Next Generation Sequencing applicato alle neoplasie del tratto genitourinario" al convegno "il confine tra benigno e maligno: dalla morfologia alla patologia molecolare.Sorrento 5-7 Ottobre 2020
- Relatore su invito con la relazione "L' Anatomia Patologica nell'era del COVID: Impatto sulla diagnostica istologica e molecolare" al XXVIII Congresso Nazionale AITIC Padova, 25-27 Ottobre 2021
- Relatore e moderatore della sessione di Uropatologia con la relazione "Esperienza di PDTA a Bologna: il patologo".Congresso Annuale SIAPeC-IAP 2021.
- Relatore su invito al convegno digitale Approccio multidisciplinare alla gestione del paziente con NSCLC EGFR-mutato negli stadi precoci" 29Aprile 2022.
- Relatore su invito con la relazione "La medicina di precisione nel carcinoma della prostata avanzato: mutazioni di BRCA1-2 e PARPi" al XXIX Congresso della Associazione degli Urologi Ospedalieri (AURO), Napoli 19-21 Maggio 2022
- Relatore su invito come delegato SIAPEC al Convegno "MINICOUNSELING: definizione di un percorso nel paziente con Carcinoma Prostatico mutato" - MINI-CAP - Bologna 3 Marzo 2023
- Relatore su invito con la relazione "Prostate cancer: molecularinvestigation for personalizedprognosis and therapy al Congresso Giornate Urologiche Sassolesi" Fiorano Modenese 7-8 luglio 2023

- Relatore su invito con la relazione “Homologous recombination deficiency in prostate cancer, prognostic and therapeutic insights” al webinar SIAPEC Webinar Patologia neoplastica del tratto urogenitale: dalla letteratura al microscopio. 16 Maggio 2024.

Partecipazione in qualità di relatore a congressi e convegni di interesse internazionale

- Invited speaker with the presentation “Urinary biomarkers for prostate cancer?” at the 9th European Multidisciplinary Congress on Urological Cancers (EMUC17), Barcelona, Spain, 16-19 November 2017
- Invited speaker with the presentation “Current applications of liquid biopsies: what we need to know before starting using them?” at the 11th European Multidisciplinary Congress on Urological Cancers (EMUC19), Vienna, Austria, 14-17 November 2019
- Invited speaker at the Workshop “Recent scientific developments in penile cancer in connection with clinical pathology research” at the Meeting of the European Association of Urology, Urological Research (ESUR22), Innsbruck, Austria, 13-15 October 2022
- Invited Speaker with the presentation “WHO classification 2022 on renal cancer: What is new?” at the UROonco2023 meeting of the European Association of Urology, Gothenburg, Sweden, June 30–July 2, 2023.

Partecipazione a seminari di interesse internazionale

- Invited to hold the seminar entitled “Liquid biopsy: a new frontier for molecular diagnostics” Research Seminars in medicine – trends in biomedicine. November 27th 2019. Faculty of Medical Science at Örebro University, Örebro, Svezia
- Invited to hold the seminar entitled “Immunotherapy of solid tumors: what role in prostate cancer?” September 22nd 2019. Department of Urology at Örebro University, Örebro, Svezia

Produzione scientifica

Pubblicazioni in extenso 1993-2024 riportate in ordine cronologico partendo dalla più recente

Evidenziato con sottolineatura se primo, ultimo, corresponding author

1. Di Sciascio L, Orsatti A, Ambrosi F, Franchini E, Massari F, Mollica V, Bianchi FM, Colecchia M, De Leo A, Acosta AM, Lobo J, **Fiorentino M**, Ricci C. Characterization of testicular embryonic-type neuroectodermal tumor and embryonic-type neuroectodermal tissue admixed with mature neuro-glial tissue using a broad immunohistochemical panel. Virchows Arch. 2024 Sep 11. doi: 10.1007/s00428-024-03911-8. Epub ahead of print. PMID: 39259293.
2. Ricci C, Ambrosi F, Grillini A, Grillini M, Mollica V, **Fiorentino M**, Sangoi AR, De Leo A, Idrees MT, Ulbright TM, Acosta AM. Immunophenotypical assessment supports that post-chemotherapy glandular tumours of germ cell origin straddle between glandular yolk sac tumour and 'somatic-type' adenocarcinoma. Histopathology. 2024 Oct;85(4):695-698. doi: 10.1111/his.15277. Epub 2024 Jul 1. PMID: 38952141.
3. Surucu A, de Biase D, Ricci C, di Sciascio L, Collins K, Idrees MT, Ebare K, **Fiorentino M**, Bridge JA, Ulbright TM, Acosta AM. Beta-Catenin Alterations in Postchemotherapy Yolk Sac Tumor, Postpubertal-Type With Enteroblastic Features. Mod Pathol. 2024 Jul;37(7):100513. doi: 10.1016/j.modpat.2024.100513. Epub 2024 May 17. PMID: 38763421.

4. Kitagawa Y, De Biase D, Ricci C, Cornejo KM, **Fiorentino M**, Collins K, Idrees MT, Colecchia M, Ulbright TM, Acosta AM. β -Catenin alterations in testicular Leydig cell tumour: a immunohistochemical and molecular analysis. *Histopathology*. 2024 Jul;85(1):75-80. doi: 10.1111/his.15175. Epub 2024 Mar 26. PMID: 38530207.
5. Raju SA, Greenaway EA, Schieppatti A, Arpa G, Vecchione N, Jian C, Grobler C, Maregatti M, Green O, Bowker-Howell FJ, Shiha MG, Penny HA, Cross SS, Ciacci C, Rostami K, Ahmadipour S, Moradi A, Rostami-Nejad M, Biagi F, Volta U, **Fiorentino M**, Lebowitz B, Green PH, Lewis S, Molina-Infante J, Mata-Romero P, Vaira V, Elli L, Soykan I, Ensari A, Sanders DS. New entity of adult ultra-short coeliac disease: the first international cohort and case-control study. *Gut*. 2024 Jun 6;73(7):1124-1130. doi: 10.1136/gutjnl-2023-330913. PMID: 38499339.
6. Rosellini M, Mollica V, Marchetti A, Coluccelli S, Giunchi F, Tassinari E, Ricci C, **Fiorentino M**, Tallini G, De Biase D, Massari F. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis. *Pathol Res Pract*. 2024 Feb;254:155142. doi: 10.1016/j.prp.2024.155142. Epub 2024 Jan 17. PMID: 38277752.
7. Ricci C, Ambrosi F, Grillini A, Massari F, **Fiorentino M**, Colecchia M, Ulbright TM, Acosta AM. Analysis of GATA3 and FOXA2 expression suggests that downregulation of genes involved in the maintenance of a mature yolk sac tumor phenotype may underlie sarcomatoid transformation. *Virchows Arch*. 2024 Apr;484(4):709-713. doi: 10.1007/s00428-023-03725-0. Epub 2023 Dec 23.
8. Mollica V, Tassinari E, Santoni M, Marchese PV, Giunchi F, Maloberti T, Tateo V, Ricci C, Rosellini M, Marchetti A, **Fiorentino M**, Biase D, Massari F. TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab. *Pathol Res Pract*. 2024 Jan;253:155008. doi: 10.1016/j.prp.2023.155008. Epub 2023 Dec 8.
9. Destefanis N, Fiano V, Milani L, Vasapolli P, **Fiorentino M**, Giunchi F, Lianas L, Del Rio M, Frexia F, Pireddu L, Molinaro L, Cassoni P, Papotti MG, Gontero P, Callaris G, Oderda M, Ricardi U, Iorio GC, Fariselli P, Isaevska E, Akre O, Zelic R, Pettersson A, Zugna D, Richiardi L. Cohort profile: the Turin prostate cancer prognostication (TPCP) cohort. *Front Oncol*. 2023 Oct 6;13:1242639. doi:10.3389/fonc.2023.1242639.
10. Ricci C, Ambrosi F, Franceschini T, Giunchi F, Grillini A, Franchini E, Grillini M, Schiavina R, Massari F, Mollica V, Tateo V, Bianchi FM, Bianchi L, Droghetti M, Maloberti T, Tallini G, Colecchia M, Acosta AM, Lobo J, Trpkov K, **Fiorentino M**, de Biase D. Evaluation of an institutional series of low-grade oncocyctic tumor (LOT) of the kidney and review of the mutational landscape of LOT. *Virchows Arch*. 2023 Nov;483(5):687-698. doi: 10.1007/s00428-023-03673-9. Epub 2023 Oct 17.
11. Gaudio C, Mottola M, Bianchi L, Corcioni B, Braccischi L, Tomassoni MT, Cattabriga A, Coccoza MA, Giunchi F, Schiavina R, Fanti S, **Fiorentino M**, Brunocilla E, Mosconi C, Bevilacqua A. An Apparent Diffusion Coefficient-Based Machine Learning Model Can Improve Prostate Cancer Detection in the Grey Area of the Prostate Imaging Reporting and Data System Category 3: A Single-Centre Experience. *Cancers (Basel)*. 2023 Jun 30;15(13):3438. doi: 10.3390/cancers15133438. PMID: 37444548; PMCID: PMC10340607.
12. Gaudio C, Renzetti B, De Fino C, Corcioni B, Ciccarese F, Bianchi L, Schiavina R, Droghetti M, Giunchi F, Brunocilla E, **Fiorentino M**. Multiparametric magnetic resonance imaging for the differential diagnosis between granulomatous prostatitis and prostate cancer: a literature review to an intriguing diagnostic challenge. *Front Oncol*. 2023 Jun 5;13:1178430. Doi 10.3389/fonc.2023.1178430.
13. Ricci C, Ambrosi F, Franceschini T, Giunchi F, Di Filippo G, Franchini E, Massari F, Mollica V, Tateo V, Bianchi FM, Colecchia M, Acosta AM, **Fiorentino M**. FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type. *Histopathology*. 2023 Sep;83(3):465-476. doi: 10.1111/his.14968. Epub 2023 Jun 14.
14. Maloberti T, De Leo A, Coluccelli S, Sanza V, Gruppioni E, Altimari A, Zagnoni S, Giunchi F, Vasuri F, **Fiorentino M**, Mollica V, Ferrari S, Miccoli S, Visani M, Turchetti D, Massari F, Tallini G, de Biase D. Multi-Gene Next-Generation Sequencing Panel for Analysis of *BRCA1* and *BRCA2* and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer. *Int J Mol Sci*. 2023 May 18;24(10):8940. doi:10.3390/ijms24108940.
15. Ricci C, Dika E, Corti B, Lambertini M, Ambrosi F, Cappilli S, Grillini M, Filippo GD, Franchini E, Maloberti T, **Fiorentino M**, Tallini G, Biase D. "Paradoxical" p16 overexpression in cutaneous melanoma: Molecular and

immunohistochemical analysis of a rare phenomenon with a focus on cell cycle regulatory molecules. *Pathol Res Pract.* 2023 Jul;247:154564. Doi 10.1016/j.prp.2023.154564. Epub 2023 May 23.

16. Melotti S, Ambrosi F, Franceschini T, Giunchi F, Filippo GD, Franchini E, Massari F, Mollica V, Tateo V, Bianchi FM, Colecchia M, Acosta AM, Lobo J, **Fiorentino M**, Ricci C. TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis. *Pathol Res Pract.* 2023 Jul;247:154540. doi: 10.1016/j.prp.2023.154540. Epub 2023 May 18.
17. Iyer HS, Vasselkiv JB, Stopsack KH, Roscoe C, DeVille NV, Zhang Y, Penney KL, Balk SP, **Fiorentino M**, Hart JE, James P, De Vivo I, Mucci LA, Laden F, Rebbeck TR. Influence of Neighborhood Social and Natural Environment on Prostate Tumor Histology in a Cohort of Male Health Professionals. *Am J Epidemiol.* 2023 Sep 1;192(9):1485-1498. doi: 10.1093/aje/kwad112.
18. Piazza P, Bianchi L, **Fiorentino M**, Gaudiano C, Giunchi F, Brunocilla E, Schiavina R. The new classification of renal cell carcinoma: what is the clinical issue? *Minerva Urol Nephrol.* 2023 Jun;75(3):269-271. doi: 10.23736/S2724-6051.23.05293-X. Epub 2023 Mar 22.
19. Ricci C, Altavilla MV, Corti B, Pasquini E, Presutti L, Baietti AM, Amorosa L, Balbi T, Baldovini C, Ambrosi F, Grillini M, D'Errico A, **Fiorentino M**, Foschini MP. PRAME Expression in Mucosal Melanoma of the Head and Neck Region. *Am J Surg Pathol.* 2023 May 1;47(5):599-610. doi: 10.1097/PAS.0000000000002032. Epub 2023 Mar 13.
20. Gaudiano C, Braccischi L, Taninokuchi Tomassoni M, Paccapelo A, Bianchi L, Corcioni B, Ciccarese F, Schiavina R, Droghetti M, Giunchi F, **Fiorentino M**, Brunocilla E, Golfieri R. Transverse prostate maximum sectional area can predict clinically significant prostate cancer in PI-RADS 3 lesions at multiparametric magnetic resonance imaging. *Front Oncol.* 2023 Feb 20;13:1082564. doi: 10.3389/fonc.2023.1082564.
21. Ricci C, Ambrosi F, Franceschini T, Giunchi F, Maracci ME, Sirolli M, Orsatti A, Chiarucci F, Franchini E, Borsato M, Massari F, Mollica V, Bianchi FM, Colecchia M, Acosta AM, **Fiorentino M**. H&E and OCT4/CD34 for the assessment of lympho-vascular invasion in seminoma and embryonal carcinoma. *Pathol Res Pract.* 2023 Feb;242:154337. doi: 10.1016/j.prp.2023.154337. Epub 2023 Jan 24.
22. Gaudiano C, Mottola M, Bianchi L, Corcioni B, Cattabriga A, Cocozza MA, Palmeri A, Coppola F, Giunchi F, Schiavina R, **Fiorentino M**, Brunocilla E, Golfieri R, Bevilacqua A. Beyond Multiparametric MRI and towards Radiomics to Detect Prostate Cancer: A Machine Learning Model to Predict Clinically Significant Lesions. *Cancers (Basel).* 2022 Dec 14;14(24):6156. doi:10.3390/cancers14246156.
23. Ruzzi F, Angelicola S, Landuzzi L, Nironi E, Semprini MS, Scalambra L, Altimari A, Gruppioni E, **Fiorentino M**, Giunchi F, Ferracin M, Astolfi A, Indio V, Ardizzoni A, Gelsomino F, Nanni P, Lollini PL, Palladini A. ADK-VR2, a cell-line derived from a treatment-naïve patient with <i>SDC4-ROS1</i> fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC. *Transl Lung Cancer Res.* 2022 Nov;11(11):2216-2229. doi: 10.21037/tlcr-22-163.
24. Ma C, Zhou Y, Fanelli GN, Stopsack KH, **Fiorentino M**, Zadra G, Mucci LA, Loda M, Tyekucheva S, Penney KL. The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer. *Mol Cancer Res.* 2023 Mar 1;21(3):253-260. doi:10.1158/1541-7786.MCR-22-0627.
25. Marchese PV, Mollica V, Tassinari E, De Biase D, Giunchi F, Marchetti A, Rosellini M, **Fiorentino M**, Massari F. Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers. *Expert Rev Mol Diagn.* 2022 Nov;22(11):997-1008. doi: 10.1080/14737159.2022.2154148.
26. Ricci C, Ambrosi F, Franceschini T, Giunchi F, Franchini E, Massari F, Mollica V, Bianchi FM, Colecchia M, Acosta AM, **Fiorentino M**. Yolk sac tumor of postpubertal-type does not exhibit immunohistochemical loss of SMARCB1/INI1 and SMARCA4/BRG1 but choriocarcinoma? *Pathol Res Pract.* 2023 Jan;241:154269. doi: 10.1016/j.prp.2022.154269. Epub 2022 Dec 7.
27. Droghetti M, Bianchi L, Beretta C, Balestrazzi E, Costa F, Feruzzi A, Piazza P, Roveroni C, Gaudiano C, Corcioni B, Giunchi F, **Fiorentino M**, Golfieri R, Schiavina R, Brunocilla E. Site-specific concordance of targeted and systematic biopsy cores at the index lesion on multiparametric magnetic resonance: can we spare the double-tap? *World J Urol.* 2023 Jan;41(1):27-33. doi:10.1007/s00345-022-04229-3. Epub 2022 Dec 5.

28. Ercolino A, Manes F, Vasuri F, Bianchi L, Garofalo M, Piazza P, Corcioni B, Schiavina R, Golfieri R, **Fiorentino M**, Colecchia M, Brunocilla E. A case report of myoid gonadal stromal tumor treated with testis sparing surgery. *Transl Androl Urol*. 2022 Oct;11(10):1458-1465. doi: 10.21037/tau-22-179.
29. Ciliberto G, Canfora M, Terrenato I, Agnoletto C, Agustoni F, Amoroso L, Baldassarre G, Curigliano G, Delmonte A, De Luca A, **Fiorentino M**, Gregorc V, Ibrahim T, Lazzari C, Mastronuzzi A, Pronzato P, Santoro A, Scambia G, Tommasi S, Vingiani A, Giacomini P, De Maria R. Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer. *J Exp Clin Cancer Res*. 2022 Oct 17;41(1):305. doi: 10.1186/s13046-022-02512-0.
30. Stopsack KH, Su XA, Vasselkiv JB, Graff RE, Ebot EM, Pettersson A, Lis RT, **Fiorentino M**, Loda M, Penney KL, Lotan TL, Mucci LA. Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions. *Mol Cancer Res*. 2023 Jan 3;21(1):14-23. doi: 10.1158/1541-7786.MCR-22-0446.
31. Orsatti A, Sirolli M, Ambrosi F, Franceschini T, Giunchi F, Franchini E, Grillini M, Massari F, Mollica V, Bianchi FM, Colecchia M, **Fiorentino M**, Ricci C. SOX2 and PRAME in the "reprogramming" of seminoma cells. *Pathol Res Pract*. 2022 Sep;237:154044. doi: 10.1016/j.prp.2022.154044. Epub 2022 Jul 28.
32. Noronha A, Belugali Nataraj N, Lee JS, Zhitomirsky B, Oren Y, Oster S, Lindzen M, Mukherjee S, Will R, Ghosh S, Simoni-Nieves A, Verma A, Chatterjee R, Borgoni S, Robinson W, Sinha S, Brandis A, Kerr DL, Wu W, Sekar A, Giri S, Chung Y, Drago-Garcia D, Danysh BP, Lauriola M, **Fiorentino M**, Ardizzoni A, Oren M, Blakely CM, Ezike J, Wiemann S, Parida L, Bivona TG, Aqeilan RI, Brugge JS, Regev A, Getz G, Ruppin E, Yarden Y. AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer. *Cancer Discov*. 2022 Nov 2;12(11):2666-2683. doi: 10.1158/2159-8290.CD-22-0111.
33. Droghetti M, Bianchi L, Gaudiano C, Corcioni B, Rustici A, Piazza P, Beretta C, Balestrazzi E, Costa F, Feruzzi A, Salvador M, Giunchi F, **Fiorentino M**, Golfieri R, Schiavina R, Brunocilla E. Comparison of prostate cancer detection rate at targeted biopsy of hub and spoke centers mpMRI: experience matters. *Minerva Urol Nephrol*. 2023 Feb;75(1):42-49. doi: 10.23736/S2724-6051.22.04932-1.
34. Marchese PV, Mollica V, De Biase D, Giunchi F, Tassinari E, Marchetti A, Rosellini M, Nuvola G, Maloberti T, **Fiorentino M**, Massari F. A hypothesis- generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy. *Pathol Res Pract*. 2022 Aug;236:153983. doi: 10.1016/j.prp.2022.153983. Epub 2022 Jun 13.
35. Di Sciascio L, Ambrosi F, Franceschini T, Giunchi F, Franchini E, Massari F, Bianchi FM, Colecchia M, **Fiorentino M**, Ricci C. Could double stain for p53/CK20 be a useful diagnostic tool for the appropriate classification of flat urothelial lesions? *Pathol Res Pract*. 2022 Jun;234:153937. doi:10.1016/j.prp.2022.153937. Epub 2022 May 6. PMID: 35561522.
36. Ambrosi F, Giunchi F, Capizzi E, Cancellieri A, Trisolini R, Ardizzoni A, **Fiorentino M**, Ricci C. Interobserver agreement of PD-L1 (SP263) assessment in advanced NSCLC on cytological smears and histological samples. *Pathol Res Pract*. 2022 May;233:153893. doi: 10.1016/j.prp.2022.153893. Epub 2022 Apr 12.
37. Ricci C, Dika E, Lambertini M, Ambrosi F, Grillini M, Chillotti S, Corradini AG, Veronesi G, **Fiorentino M**, Corti B. Hematoxylin and eosin or double stain for CD34/SOX10: Which is better for the detection of lymphovascular invasion in cutaneous melanoma? *Pathol Res Pract*. 2022 May;233:153876. doi: 10.1016/j.prp.2022.153876.
38. Ricci C, Dika E, Lambertini M, Ambrosi F, Chiarucci F, Chillotti S, **Fiorentino M**, Fabbri E, Tassone D, Veronesi G, Tartari F, Corti B. The EORTC protocol for sentinel lymph node biopsy (SLNB) reveals a high number of nodal nevi and a strong association with nevus-associated melanoma. *Pathol Res Pract*. 2022 May;233:153805. doi: 10.1016/j.prp.2022.153805. Epub 2022 Mar 28.
39. Gaudiano C, Ciccarese F, Bianchi L, Corcioni B, De Cinque A, Giunchi F, Schiavina R, **Fiorentino M**, Brunocilla E, Golfieri R. The role of MRI in the detection of local recurrence: Added value of multiparametric approach and Signal Intensity/Time Curve analysis. *Arch Ital Urol Androl*. 2022 Mar 28;94(1):25-31. doi: 10.4081/aiua.2022.1.25.
40. Mazzeschi M, Sgarzi M, Romaniello D, Gelfo V, Cavallo C, Ambrosi F, Morselli A, Miano C, Laprovitera N, Girone C, Ferracin M, Santi S, Rihawi K, Ardizzoni A, **Fiorentino M**, D'Uva G, Györfy B, Palmer R, Lauriola M. The

autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer. *J Exp Clin Cancer Res.* 2022 Mar 29;41(1):113. doi: 10.1186/s13046-022-02309-1.

41. Cambuli F, Foletto V, Alaimo A, De Felice D, Gandolfi F, Palumbieri MD, Zaffagni M, Genovesi S, Lorenzoni M, Celotti M, Bertossio E, Mazzerro G, Bertossi A, Bisio A, Berardinelli F, Antoccia A, Gaspari M, Barbareschi M, **Fiorentino M**, Shen MM, Loda M, Romanel A, Lunardi A. Intra-epithelial non-canonical Activin A signaling safeguards prostate progenitor quiescence. *EMBO Rep.* 2022 May 4;23(5):e54049. doi: 10.15252/embr.202154049.
42. Zelic R, Giunchi F, Fridfeldt J, Carlsson J, Davidsson S, Lianas L, Mascia C, Zugna D, Molinaro L, Vincent PH, Zanetti G, Andr n O, Richiardi L, Akre O, **Fiorentino M**, Pettersson A. Prognostic Utility of the Gleason Grading System Revisions and Histopathological Factors Beyond Gleason Grade. *Clin Epidemiol.* 2022 Jan 18;14:59-70. doi: 10.2147/CLEP.S339140.
43. Stopsack KH, Tyekucheva S, Wang M, Gerke TA, Vasselkiv JB, Penney KL, Kantoff PW, Finn SP, **Fiorentino M**, Loda M, Lotan TL, Parmigiani G, Mucci LA. Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays. *Elife.* 2021 Dec 23;10:e71265. doi: 10.7554/eLife.71265.
44. Gaudiano C, Rustici A, Corcioni B, Ciccarese F, Bianchi L, Schiavina R, Giunchi F, **Fiorentino M**, Brunocilla E, Golfieri R. PI-RADS version 2.1 for the evaluation of transition zone lesions: a practical guide for radiologists. *Br J Radiol.* 2022 Mar 1;95(1131):20210916. doi: 10.1259/bjr.20210916. Epub 2022 Feb 11.
45. Compton C, De Marzo A, Debnath J, Eaton KD, Elenitoba-Johnson K, **Fiorentino M**, French CA, Fuchs TJ, Giangaspero F, Huang J, Iafrate AJ, Ittmann MM, Jensen RA, Kim AS, Loda M, Lorenz RG, Lotan TL, Maitra A, Meijer GA, Mitchell RN, Parwani AV, Pezzella F, Pikarsky E, Reis-Filho GS, Richardson AL, Rubin MA, True LD. AACR Pathology Task Force. Pathology: Hub and Integrator of Modern, Multidisciplinary [Precision] Oncology. *Clin Cancer Res.* 2022 Jan 15;28(2):265-270. doi: 10.1158/1078-0432.CCR-21-1206. Epub 2021 Dec 10.
46. Maloberti T, De Leo A, Sanza V, Merlo L, Visani M, Acquaviva G, Coluccelli S, Altimari A, Gruppioni E, Zagnoni S, Turchetti D, Miccoli S, **Fiorentino M**, D'Errico A, De Biase D, Tallini G. BRAF and MLH1 Analysis Algorithm for the Evaluation of Lynch Syndrome Risk in Colorectal Carcinoma Patients: Evidence-Based Data from the Analysis of 100 Consecutive Cases. *Journal of Molecular Pathology.* 2022; 3(3):115-124. <https://doi.org/10.3390/jmp3030011>.
47. Ricci AD, Rizzo A, Mollica V, Schiavina R, **Fiorentino M**, Brunocilla E, Ardizzoni A, Massari F. Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data. *Anticancer Drugs.* 2022 Jan 1;33(1):e61-e68. doi: 10.1097/CAD.0000000000001200.
48. Grillini M, Ricci C, Pino V, Pedrini S, **Fiorentino M**, Corti B. HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME). *Appl Immunohistochem Mol Morphol.* 2022 Jan 1;30(1):14-18. doi: 10.1097/PAI.0000000000000972.
49. Dorofte L, Gr laud D, **Fiorentino M**, Giunchi F, Ricci C, Franceschini T, Riefolo M, Davidsson S, Carlsson J, Lillsunde Larsson G, Karlsson MG. Low level of interobserver concordance in assessing histological subtype and tumor grade in patients with penile cancer may impair patient care. *Virchows Arch.* 2022 Apr;480(4):879-886. doi: 10.1007/s00428-021-03249-5.
50. Ricci C, Franceschini T, Giunchi F, Grillini M, Ambrosi F, Massari F, Mollica V, Colecchia M, **Fiorentino M**. Immunohistochemical Expression of Preferentially Expressed Antigen in Melanoma (PRAME) in the Uninvolved Background Testis, Germ Cell Neoplasia In Situ, and Germ Cell Tumors of the Testis. *Am J Clin Pathol.* 2022 May 4;157(5):644-648. doi: 10.1093/ajcp/aqab200.
51. De Maglio G, Pasello G, Dono M, **Fiorentino M**, Follador A, Sciortino M, Malapelle U, Tiseo M. The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to run the real clinical practice. *Crit Rev Oncol Hematol.* 2022 Jan;169:103561. doi: 10.1016/j.critrevonc.2021.103561. Epub 2021 Nov 29.
52. Gaudiano C, Bianchi L, De Cinque A, Corcioni B, Giunchi F, Schiavina R, **Fiorentino M**, Brunocilla E, Golfieri R. The impact of multiparametric MRI features to identify the presence of prevalent cribriform pattern in the peripheral zone tumors. *Radiol Med.* 2022 Feb;127(2):174-182. doi: 10.1007/s11547-021-01433-w.

53. Gaudiano C, Bianchi L, Corcioni B, Giunchi F, Schiavina R, Ciccarese F, Braccischi L, Rustici A, **Fiorentino M**, Brunocilla E, Golfieri R. Evaluating the performance of clinical and radiological data in predicting prostate cancer in prostate imaging reporting and data system version 2.1 category 3 lesions of the peripheral and the transition zones. *Int Urol Nephrol*. 2022 Feb;54(2):263-271. doi: 10.1007/s11255-021-03071-7.
54. Ricci C, Franceschini T, Giunchi F, Borsato M, Mollica V, Massari F, **Fiorentino M**. A preliminary study investigating the detection of lymphovascular invasion in germ cell tumors of the testis with double staining for OCT4/CD34. *Pathol Res Pract*. 2021 Nov;227:153637. doi: 10.1016/j.prp.2021.153637.
55. Rizzo A, Santoni M, Mollica V, **Fiorentino M**, Brandi G, Massari F. Microbiota and prostate cancer. *Semin Cancer Biol*. 2022 Nov;86(Pt 3):1058-1065. doi: 10.1016/j.semcancer.2021.09.007.
56. Davidsson S, **Fiorentino M**, Giunchi F, Eriksson M, Erlandsson A, Sundqvist P, Carlsson J. Infiltration of M2 Macrophages and Regulatory T Cells Plays a Role in Recurrence of Renal Cell Carcinoma. *Eur Urol Open Sci*. 2020 Aug 20;20:62-71. doi: 10.1016/j.euros.2020.06.003.
57. Bianchi L, Chessa F, Angiolini A, Cercenelli L, Lodi S, Bortolani B, Molinaroli E, Casablanca C, Droghetti M, Gaudiano C, Mottaran A, Porreca A, Golfieri R, Romagnoli D, Giunchi F, **Fiorentino M**, Piazza P, Puliatti S, Diciotti S, Marcelli E, Mottrie A, Schiavina R. The Use of Augmented Reality to Guide the Intraoperative Frozen Section During Robot-assisted Radical Prostatectomy. *Eur Urol*. 2021 Oct;80(4):480-488. doi: 10.1016/j.eururo.2021.06.020.
58. Sbravati F, Cosentino A, Lenzi J, **Fiorentino M**, Ambrosi F, Salerno A, Di Biase A, Righi B, Brusa S, Valin PS, Bruni L, Battistini B, Pagano S, Grondona AG, Labriola F, Alvisi P. Antitissue transglutaminase antibodies' normalization after starting a gluten-free diet in a large population of celiac children-a real-life experience. *Dig Liver Dis*. 2022 Mar;54(3):336-342. doi: 10.1016/j.dld.2021.06.026.
59. Zaroni L, Bianchi L, Nanni C, Pultrone C, Giunchi F, Bossert I, Matti A, Schiavina R, **Fiorentino M**, Romagnoli D, Fonti C, Lodi F, D'Errico A, Brunocilla E, Porreca A, Fanti S. [¹⁸F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial. *Eur J Nucl Med Mol Imaging*. 2021 Dec;49(1):390-409. doi: 10.1007/s00259-021-05429-6.
60. Marchetti A, Rosellini M, Mollica V, Rizzo A, Tassinari E, Nuvola G, Cimadamore A, Santoni M, **Fiorentino M**, Montironi R, Massari F. The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory? *Int J Mol Sci*. 2021 Jun 9;22(12):6237. doi: 10.3390/ijms22126237.
61. Ricci C, Ambrosi F, Dika E, Lambertini M, Chillotti S, **Fiorentino M**, Corti B. Giant (pseudo) vascular spiradenoma: a case report of an extremely rare entity with the immuno-histological demonstration of the coexistence of vascular and pseudo-vascular components. *Ital J Dermatol Venerol*. 2021 Oct;156(5):630-632. doi: 10.23736/S2784-8671.21.06883-8.
62. Rizzo A, Mollica V, Rosellini M, Marchetti A, Ricci AD, **Fiorentino M**, Battelli N, Santoni M, Massari F. Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials. *Pathol Res Pract*. 2021 Jun;222:153440. doi: 10.1016/j.prp.2021.153440.
63. Giunchi F, Franceschini T, **Fiorentino M**. A narrative review of individualized treatments of genitourinary tumors: is the future brighter with molecular evaluations? *Transl Androl Urol*. 2021 Mar;10(3):1553-1561. doi: 10.21037/tau-20-1185.
64. Dall'Olio FG, Gelsomino F, Conci N, Marcolin L, De Giglio A, Grilli G, Sperandi F, Fontana F, Terracciano M, Fragomeno B, Tober N, Manferrari G, Brocchi S, Golfieri R, **Fiorentino M**, Ardizzoni A. PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non- small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors. *Clin Lung Cancer*. 2021 Sep;22(5):423-431. doi: 10.1016/j.clcc.2021.03.005.
65. Livi V, Paioli D, Cancellieri A, Betti S, Natali F, Ferrari M, **Fiorentino M**, Trisolini R. Diagnosis and Molecular Profiling of Lung Cancer by Percutaneous Ultrasound-Guided Biopsy of Superficial Metastatic Sites Is Safe and Highly Effective. *Respiration*. 2021;100(6):515-522. doi: 10.1159/000514316.

66. Zanoni L, Mei R, Bianchi L, Giunchi F, Maltoni L, Pultrone CV, Nanni C, Bossert I, Matti A, Schiavina R, **Fiorentino M**, Fonti C, Lodi F, D'Errico A, Brunocilla E, Fanti S. The Role of [¹⁸F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [11C]Choline PET/CT and Histopathological Analysis. *Cancers (Basel)*. 2021 Mar 29;13(7):1575. doi: 10.3390/cancers13071575.
67. Pantaleo MA, Mandruzzato M, Indio V, Urbini M, Nannini M, Gatto L, Schipani A, **Fiorentino M**, Franceschini T, Ambrosini V, Di Scioscio V, Saponara M, Ianni M, Concetti S, Altimari A, Ardizzoni A, Astolfi A. Case Report: The Complete Remission of a Mixed Germ Cell Tumor With Somatic Type Malignancy of Sarcoma Type With a GCT-Oriented Therapy: Clinical Findings and Genomic Profiling. *Front Oncol*. 2021 Mar 16;11:633543. doi: 10.3389/fonc.2021.633543.
68. Borghesi M, Bianchi L, Barbaresi U, Vagnoni V, Corcioni B, Gaudiano C, **Fiorentino M**, Giunchi F, Chessa F, Garofalo M, Bertaccini A, Angelini S, Ercolino A, Casablanca C, Droghetti M, Golfieri R, Schiavina R. Diagnostic performance of MRI/TRUS fusion-guided biopsies vs. systematic prostate biopsies in biopsy-naïve, previous negative biopsy patients and men undergoing active surveillance. *Minerva Urol Nephrol*. 2021 Jun;73(3):357-366. doi:10.23736/S2724-6051.20.03758-3.
69. Rizzo A, Mollica V, Giunchi F, Dall'Olio FG, Rosellini M, Marchetti A, Franceschini T, Schiavina R, Brunocilla E, **Fiorentino M**, Ardizzoni A, Massari F. Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience. *Pathol Res Pract*. 2021 Apr;220:153410. doi: 10.1016/j.prp.2021.153410.
70. Mollica V, Franceschini T, Gruppioni E, Rizzo A, Ricci C, Schiavina R, Brunocilla E, Ardizzoni A, **Fiorentino M**, Giunchi F, Massari F. Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing. *Pathol Res Pract*. 2021 Mar;219:153350. doi:10.1016/j.prp.2021.153350.
71. Zelic R, Giunchi F, Lianas L, Mascia C, Zanetti G, Andr n O, Fridfeldt J, Carlsson J, Davidsson S, Molinaro L, Vincent PH, Richiardi L, Akre O, **Fiorentino M**, Pettersson A. Interchangeability of light and virtual microscopy for histopathological evaluation of prostate cancer. *Sci Rep*. 2021 Feb 5;11(1):3257. doi: 10.1038/s41598-021-82911-z.
72. Franceschini T, Giunchi F, Mollica V, Altimari A, Capizzi E, Banfi M, Schiavina R, **Fiorentino M**, Massari F. Renal Tumors with Oncocytic and Papillary Features: A Phenotypic and Genotypic Study. *Diagnostics (Basel)*. 2021 Jan 28;11(2):184. doi: 10.3390/diagnostics11020184.
73. Pernar CH, Parmigiani G, Giovannucci EL, Rimm EB, Tyekucheva S, Loda M, Finn SP, Vander Heiden MG, **Fiorentino M**, Ebot EM, Mucci LA. Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer. *Cancer Epidemiol Biomarkers Prev*. 2021 Apr;30(4):751-756. doi: 10.1158/1055-9965.EPI-20-1461.
74. Giunchi F, Massari F, Altimari A, Gruppioni E, Nobili E, **Fiorentino M**, Ardizzoni A. Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers. *Diagnostics (Basel)*. 2020 Dec 20;10(12):1109. doi:10.3390/diagnostics10121109.
75. Ricci C, Capizzi E, Giunchi F, Casolari L, Gelsomino F, Rihawi K, Natali F, Livi V, Trisolini R, **Fiorentino M**, Ardizzoni A. Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study. *Ther Adv Med Oncol*. 2020 Nov 30;12:1758835920954802. doi: 10.1177/1758835920954802.
76. Mollica V, Rizzo A, Tassinari E, Giunchi F, Schiavina R, **Fiorentino M**, Brunocilla E, Ardizzoni A, Massari F. Prognostic and predictive factors of nivolumab in patients with metastatic renal cell carcinoma: a single center study. *Anticancer Drugs*. 2021 Jan 1;32(1):74-81. doi:10.1097/CAD.0000000000001017.
77. Schiavina R, Droghetti M, Novara G, Bianchi L, Gaudiano C, Panebianco V, Borghesi M, Piazza P, Mineo Bianchi F, Guerra M, Corcioni B, **Fiorentino M**, Giunchi F, Verze P, Pultrone C, Golfieri R, Porreca A, Mirone V, Brunocilla E. The role of multiparametric MRI in active surveillance for low-risk prostate cancer: The ROMAS randomized controlled trial. *Urol Oncol*. 2021 Jul;39(7):433.e1-433.e7. doi: 10.1016/j.urolonc.2020.10.018.
78. Penney KL, Tyekucheva S, Rosenthal J, El Fandy H, Carelli R, Borgstein S, Zadra G, Fanelli GN, Stefanizzi L, Giunchi F, Pomerantz M, Peisch S, Coulson H, Lis R, Kibel AS, **Fiorentino M**, Umeton R, Loda M. Metabolomics

of Prostate Cancer Gleason Score in Tumor Tissue and Serum. *Mol Cancer Res.* 2021 Mar;19(3):475-484. doi: 10.1158/1541-7786.MCR-20-0548.

79. Sirri R, Tura G, Budai J, Beraldo P, **Fiorentino M**, Barbé T, Galeotti M, Sarli G, Mandrioli L. Histological and immunohistochemical characterization of 17 gonadal tumours in koi carp (*Cyprinus carpio koi*). *J Fish Dis.* 2021 Mar;44(3):273-285. doi: 10.1111/jfd.13280.
80. Stopsack KH, Su XA, Vaselkiv JB, Graff RE, Ebot EM, Pettersson A, Lis RT, **Fiorentino M**, Loda M, Penney KL, Lotan TL, Mucci LA. Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions. *Mol Cancer Res.* 2023 Jan 3;21(1):14-23. doi: 10.1158/1541-7786.MCR-22-0446.
81. Dall'Olio FG, Conci N, Rossi G, **Fiorentino M**, De Giglio A, Grilli G, Altimari A, Gruppioni E, Filippini DM, Di Federico A, Nuvola G, Ardizzoni A. Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients - A single centre experience. *Lung Cancer.* 2020 Nov;149:5-9. doi: 10.1016/j.lungcan.2020.08.008.
82. Damiani S, **Fiorentino M**, De Palma A, Foschini MP, Lazzarotto T, Gabrielli L, Viale PL, Attard L, Riefolo M, D'Errico A. Pathological post-mortem findings in lungs infected with SARS-CoV-2. *J Pathol.* 2021 Jan;253(1):31-40. doi: 10.1002/path.5549.
83. Rizzo A, Mollica V, Cimadamore A, Santoni M, Scarpelli M, Giunchi F, Cheng L, Lopez-Beltran A, **Fiorentino M**, Montironi R, Massari F. Is There a Role for Immunotherapy in Prostate Cancer? *Cells.* 2020 Sep 8;9(9):2051. doi:10.3390/cells9092051.
84. Schiavina R, Bianchi L, Lodi S, Cercenelli L, Chessa F, Bortolani B, Gaudio C, Casablanca C, Droghetti M, Porreca A, Romagnoli D, Golfieri R, Giunchi F, **Fiorentino M**, Marcelli E, Diciotti S, Brunocilla E. Real-time Augmented Reality Three-dimensional Guided Robotic Radical Prostatectomy: Preliminary Experience and Evaluation of the Impact on Surgical Planning. *Eur Urol Focus.* 2021 Nov;7(6):1260-1267. doi: 10.1016/j.euf.2020.08.004.
85. Ambrosi F, Ricci C, Malvi D, Cillia C, Ravaioli M, **Fiorentino M**, Cardillo M, Vasuri F, D'Errico A. Pathological features and outcomes of incidental renal cell carcinoma in candidate solid organ donors. *Kidney Res Clin Pract.* 2020 Dec 31;39(4):487-494. doi: 10.23876/j.krcp.20.050.
86. Lamberti G, Gelsomino F, Brocchi S, Poerio A, Melotti B, Sperandi F, Gargiulo M, Borghi C, **Fiorentino M**, Ardizzoni A. New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event. *Ther Adv Med Oncol.* 2020 Jul 24;12:1758835920913801. doi: 10.1177/1758835920913801.
87. Mollica V, Maggio I, Lopez-Beltran A, Montironi R, Cimadamore A, Cheng L, Rizzo A, Giunchi F, Schiavina R, **Fiorentino M**, Brunocilla E, Massari F. Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. *Expert Rev Anticancer Ther.* 2020 Sep;20(9):755-763. doi: 10.1080/14737140.2020.1807334.
88. Colecchia M, Bertolotti A, Paolini B, Giunchi F, Necchi A, Paganoni AM, Ricci C, **Fiorentino M**, Dagrada GP. The Leydig cell tumour Scaled Score (LeSS): a method to distinguish benign from malignant cases, with additional correlation with MDM2 and CDK4 amplification. *Histopathology.* 2021 Jan;78(2):290-299. doi: 10.1111/his.14225.
89. Trisolini R, Cancellieri A, Livi V, Annema JT, Ferrari M, Natali F, Paioli D, Conci N, Altimari A, **Fiorentino M**, Ardizzoni A. Pulmonary adenocarcinoma with psammoma bodies is associated with a specific endobronchial ultrasound pattern and a high prevalence of actionable driver mutations. *Lung Cancer.* 2020 Sep;147:204-208. doi: 10.1016/j.lungcan.2020.07.025.
90. Gelsomino F, Lamberti G, Tiseo M, Rocco D, Pasello G, Cecere FL, Chella A, Grilli G, Mandruzzato M, Tognetto M, Garassino MC, Macerelli M, Novello S, Roila F, Colantonio I, Grossi F, **Fiorentino M**, Ardizzoni A. Atezolizumab in a Cohort of pretreated, advanced, non-small cell lung cancer patients with rare Histological Subtypes (CHANCE trial). *Ther Adv Med Oncol.* 2020 Jul 20;12:1758835920915983. doi: 10.1177/1758835920915983.

91. Franceschini T, Capizzi E, Massari F, Schiavina R, **Fiorentino M**, Giunchi F. Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer. *Pathol Res Pract*. 2020 Aug;216(8):153012. doi: 10.1016/j.prp.2020.153012.
92. Ricci C, Ambrosi F, Grillini M, Serra M, Melotti B, Gruppioni E, Altimari A, **Fiorentino M**, Dika E, Lambertini M, Corti B. Next-generation sequencing revealing TP53 mutation as potential genetic driver in dermal deep-seated melanoma arising in giant congenital nevus in adult patients: A unique case report and review of the literature. *J Cutan Pathol*. 2020 Dec;47(12):1164-1169. doi: 10.1111/cup.13802.
93. Fankhauser CD, Penney KL, Gonzalez-Feliciano AG, Clarke NW, Hermanns T, Stopsack KH, **Fiorentino M**, Loda M, Mahal B, Gerke TA, Preston MA, Mucci LA. Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. *Eur Urol*. 2020 Oct;78(4):637-639. doi: 10.1016/j.eururo.2020.05.035.
94. Droghetti M, Ercolino A, Piazza P, Bianchi L, Fabbrizio B, Giunchi F, Mineo Bianchi F, Barbaresi U, Casabianca C, Tonin E, Mottaran A, **Fiorentino M**, Schiavina R, Brunocilla E. Secondary bladder amyloidosis due to Crohn's disease: a case report and literature review. *CEN Case Rep*. 2020 Nov;9(4):413-417. doi: 10.1007/s13730-020-00497-3.
95. Stopsack KH, Gerke T, Zareba P, Pettersson A, Chowdhury D, Ebot EM, Flavin R, Finn S, Kantoff PW, Stampfer MJ, Loda M, **Fiorentino M**, Mucci LA. Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. *Carcinogenesis*. 2020 Jul 14;41(7):904-908. doi: 10.1093/carcin/bgaa061.
96. Mollica V, Rizzo A, Montironi R, Cheng L, Giunchi F, Schiavina R, Santoni M, **Fiorentino M**, Lopez-Beltran A, Brunocilla E, Brandi G, Massari F. Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. *Cancers (Basel)*. 2020 Jun 2;12(6):1449. doi: 10.3390/cancers12061449.
97. Natali F, Cancellieri A, Giunchi F, De Silvestri A, Livi V, Ferrari M, Paioli D, Betti S, **Fiorentino M**, Trisolini R. Interobserver agreement between pathologist, pulmonologist and molecular pathologist to estimate the tumour burden in rapid on-site evaluation smears from endosonography and guided bronchoscopy. *Cytopathology*. 2020 Jul;31(4):303-309.
98. Minari R, Mazzaschi G, Bordi P, Gnetti L, Alberti G, Altimari A, Gruppioni E, Sperandi F, Parisi C, Guaitoli G, Bettelli S, Longo L, Bertolini F, Pagano M, Bonelli C, Tagliavini E, Nicoli D, Ubiali A, Zangrandi A, Trubini S, Proietto M, **Fiorentino M**, Tiseo M; DETECTION Study Group. Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study. *Clin Lung Cancer*. 2020 Sep;21(5):e464-e473. doi: 10.1016/j.clc.2020.02.021.
99. Davidsson S, **Fiorentino M**, Giunchi F, Eriksson M, Erlandsson A, Sundqvist P, Carlsson J. Infiltration of M2 Macrophages and Regulatory T Cells Plays a Role in Recurrence of Renal Cell Carcinoma. *Eur Urol Open Sci*. 2020 Aug 20;20:62-71. doi: 10.1016/j.euros.2020.06.003.
100. Junker K, Eckstein M, **Fiorentino M**, Montironi R. PD1/PD-L1 Axis in Uro- oncology. *Curr Drug Targets*. 2020;21(13):1293-1300. doi: 10.2174/1389450121666200326123700.
101. Cavazzoni A, Digiacomo G, Alfieri R, La Monica S, Fumarola C, Galetti M, Bonelli M, Cretella D, Barili V, Zecca A, Giovannetti E, **Fiorentino M**, Tiseo M, Petronini PG, Ardizzoni A. Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non- Small-Cell Lung Cancer. *Cancers (Basel)*. 2020 Mar 12;12(3):666. doi:10.3390/cancers12030666.
102. Calì A, Brunelli M, Segala D, Pedron S, Remo A, Ammendola S, Munari E, Pierconti F, Mosca A, Bollito E, Sidoni A, Fisogni S, Sacco C, Canu L, Sentinelli S, Fraccon AP, **Fiorentino M**, Scott C, Milella M, Porta C, Argani P, Martignoni G. Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets. *Pathology*. 2020 Apr;52(3):297-309. doi:10.1016/j.pathol.2019.11.006.
103. Giunchi F, Franceschini T, Gruppioni E, Altimari A, Capizzi E, Massari F, Schiavina R, Brunelli M, Martignoni G, **Fiorentino M**. Similarities and Differences between Clear Cell Tubulo-Papillary and Conventional

104. Dika E, Veronesi G, Altimari A, Riefolo M, Ravaioli GM, Piraccini BM, Lambertini M, Campione E, Gruppioni E, **Fiorentino M**, Melotti B, Ferracin M, Patrizi A. BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients. *Am J Clin Pathol*. 2020 Apr 15;153(5):664-671. doi: 10.1093/ajcp/aqz209.
105. Giunchi F, Gevaert T, Scarpelli M, **Fiorentino M**. Status of Programmed DeathLigand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms. *Curr DrugTargets*. 2020;21(13):1286-1292. doi: 10.2174/1389450121666200123124642.
106. Trisolini R, Cancellieri A, Livi V, Annema JT, Ferrari M, Natali F, Paioli D, Conci N, Altimari A, **Fiorentino M**, Ardizzoni A. Pulmonary adenocarcinoma with psammoma bodies is associated with a specific endobronchial ultrasound pattern and a high prevalence of actionable driver mutations. *Lung Cancer*. 2020 Sep;147:204-208. doi: 10.1016/j.lungcan.2020.07.025.
107. Dika E, Lambertini M, Patrizi A, Misciali C, Altimari A, **Fiorentino M**, Melotti B, Corti B, Riefolo M, Veronesi G. Frequency of somatic mutations in head and neck melanoma: A single-institution experience. *Pigment Cell Melanoma Res*. 2020 May;33(3):515-517. doi: 10.1111/pcmr.12864.
108. Cinausero M, Laprovitera N, De Maglio G, Gerratana L, Riefolo M, Macerelli M, **Fiorentino M**, Porcellini E, Buoro V, Gelsomino F, Squadrilli A, Fasola G, Negrini M, Tiseo M, Ferracin M, Ardizzoni A. KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. *Ther Adv Med Oncol*. 2019 Nov 14;11:1758835919885540. doi: 10.1177/1758835919885540.
109. Vasuri F, Nerpiti A, Zagnoni S, Ravaioli M, D'Errico A, **Fiorentino M**. Pd- ligand 1 is expressed in inflammatory cells but not in neoplastic cells in hepatocellular carcinoma: An immunohistochemical study. *Acta Histochem*. 2020 Jan;122(1):151468. doi: 10.1016/j.acthis.2019.151468.
110. Gatto L, Del Gaudio M, Ravaioli M, Cescon M, Tonini V, Cervellera M, Franceschelli A, Pirini MG, Di Scioscio V, Buia F, Niro F, Capizzi E, **Fiorentino M**, Astolfi A, Indio V, Nannini M, Pantaleo MA, Saponara M. Paratesticular Mesenchymal Malignancies: A Single-Center Case Series, Clinical Management, and Review of Literature. *Integr Cancer Ther*. 2020 Jan-Dec;19:1534735419900554. doi: 10.1177/1534735419900554.
111. Di Nunno V, Mollica V, Schiavina R, Nobili E, **Fiorentino M**, Brunocilla E, Ardizzoni A, Massari F. Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2020 Apr;18(2):e83-e90. doi: 10.1016/j.clgc.2019.08.007.
112. Dika E, Patrizi A, Lambertini M, Manuelpillai N, **Fiorentino M**, Altimari A, Ferracin M, Lauriola M, Fabbri E, Campione E, Veronesi G, Scarfi F. Estrogen Receptors and Melanoma: A Review. *Cells*. 2019 Nov 19;8(11):1463. doi: 10.3390/cells8111463.
113. Bianchi L, Schiavina R, Borghesi M, Chessa F, Casablanca C, Angiolini A, Ercolino A, Pultrone CV, Mineo Bianchi F, Barbaresi U, Piazza P, Manferrari F, Bertaccini A, **Fiorentino M**, Ferro M, Porreca A, Marcelli E, Brunocilla E. Which patients with clinical localized renal mass would achieve the trifecta after partial nephrectomy? The impact of surgical technique. *Minerva Urol Nefrol*. 2020 Jun;72(3):339-349. doi: 10.23736/S0393-2249.19.03485-4.
114. Labbé DP, Zadra G, Yang M, Reyes JM, Lin CY, Cacciatore S, Ebot EM, Creech AL, Giunchi F, **Fiorentino M**, Elfandy H, Syamala S, Karoly ED, Alshalalfa M, Erho N, Ross A, Schaeffer EM, Gibb EA, Takhar M, Den RB, Lehrer J, Karnes RJ, Freedland SJ, Davicioni E, Spratt DE, Ellis L, Jaffe JD, D'Amico AV, Kantoff PW, Bradner JE, Mucci LA, Chavarro JE, Loda M, Brown M. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. *Nat Commun*. 2019 Sep 25;10(1):4358. doi: 10.1038/s41467-019-12298-z.
115. Zhang Y, Zhou CK, Rencsok EM, Fall K, Lotan TL, Loda M, Giunchi F, PlatzEA, De Marzo AM, Mucci LA, **Fiorentino M**, Ebot EM. A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer. *Cancer Epidemiol Biomarkers Prev*. 2019 Dec;28(12):2047-2054. doi: 10.1158/1055-9965.EPI-19-0713.

116. Franceschini T, Giunchi F, Montironi R, Scarpelli M, Lopez-Beltran A, Cheng L, **Fiorentino M**. Liquid biopsies in urological cancers: what we need to know before starting using them. *Expert Rev Mol Diagn*. 2020 Feb;20(2):135-139. doi: 10.1080/14737159.2019.1665508.
117. Capizzi E, Dall'Olio FG, Gruppioni E, Sperandi F, Altimari A, Giunchi F, **Fiorentino M**, Ardizzoni A. Clinical significance of ROS1 5' deletions in non- small cell lung cancer. *Lung Cancer*. 2019 Sep;135:88-91. doi:10.1016/j.lungcan.2019.07.017.
118. Di Nunno V, Mollica V, Santoni M, Gatto L, Schiavina R, **Fiorentino M**, Brunocilla E, Ardizzoni A, Massari F. New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. *Clin Genitourin Cancer*. 2019 Oct;17(5):e871-e877. doi:10.1016/j.clgc.2019.07.001.
119. Broccoli A, Bertuzzi C, **Fiorentino M**, Morigi A, Stefoni V, Agostinelli C, Argnani L, Cavo M, Zinzani PL. BRAF/V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia. *Onco Targets Ther*. 2019 Jun 20;12:4807-4812. doi: 10.2147/OTT.S202061.
120. Livi V, Ardizzoni A, Cancellieri A, Natali F, Ferrari M, Paioli D, De Biase D, Capizzi E, Tallini G, **Fiorentino M**, Trisolini R. Adequacy of endosonography- derived samples from peribronchial or periesophageal intrapulmonary lesions for the molecular profiling of lung cancer. *Clin Respir J*. 2019 Sep;13(9):590-597. doi: 10.1111/crj.13063.
121. Di Nunno V, Mollica V, Brunelli M, Gatto L, Schiavina R, **Fiorentino M**, Santoni M, Montironi R, Calò A, Eccher A, Milella M, Martignoni G, Brunocilla E, Massari F. A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. *Mol Diagn Ther*. 2019 Oct;23(5):569-577. doi: 10.1007/s40291-019-00414-0.
122. Di Nunno V, Frega G, Santoni M, Gatto L, **Fiorentino M**, Montironi R, Battelli N, Brandi G, Massari F. BAP1 in solid tumors. *Future Oncol*. 2019 Jun;15(18):2151-2162. doi: 10.2217/fon-2018-0915.
123. Bianchi L, Schiavina R, Borghesi M, Casablanca C, Chessa F, Mineo Bianchi F, Pultrone C, Vagnoni V, Ercolino A, Dababneh H, **Fiorentino M**, Brunocilla E. Patterns of positive surgical margins after open radical prostatectomy and their association with clinical recurrence. *Minerva Urol Nefrol*. 2020 Aug;72(4):464-473. doi: 10.23736/S0393-2249.19.03269-7.
124. Repaci A, Vicennati V, Paccapelo A, Cavicchi O, Salituro N, Monari F, de Biase D, Tallini G, Altimari A, Gruppioni E, **Fiorentino M**, Pagotto U. BRAF V600E Status and Stimulated Thyroglobulin at Ablation Time Increase Prognostic Value of American Thyroid Association Classification Systems for Persistent Disease in Differentiated Thyroid Carcinoma. *Int J Endocrinol*. 2019 Apr 7;2019:3081497. doi: 10.1155/2019/3081497.
125. Carlsson J, Sundqvist P, Kosuta V, Fält A, Giunchi F, **Fiorentino M**, Davidsson S. PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma. *Appl Immunohistochem Mol Morphol*. 2020 Mar;28(3):213-220. doi: 10.1097/PAI.0000000000000766.
126. Davidsson S, Carlsson J, Giunchi F, Harlow A, Kirrander P, Rider J, **Fiorentino M**, Andrén O. PD-L1 Expression in Men with Penile Cancer and its Association with Clinical Outcomes. *Eur Urol Oncol*. 2019 Mar;2(2):214-221. doi: 10.1016/j.euo.2018.07.010. Epub 2018 Aug 23. PMID: 31017099.
127. Carlsson J, Christiansen J, Davidsson S, Giunchi F, **Fiorentino M**, Sundqvist P. The potential role of miR-126, miR-21 and miR-10b as prognostic biomarkers in renal cell carcinoma. *Oncol Lett*. 2019 May;17(5):4566-4574. doi:10.3892/ol.2019.10142.
128. Zelic R, Zugna D, Bottai M, Andrén O, Fridfeldt J, Carlsson J, Davidsson S, Fiano V, **Fiorentino M**, Giunchi F, Grasso C, Lianas L, Mascia C, Molinaro L, Zanetti G, Richiardi L, Pettersson A, Akre O. Estimation of Relative and Absolute Risks in a Competing-Risks Setting Using a Nested Case-Control Study Design: Example From the ProMort Study. *Am J Epidemiol*. 2019 Jun 1;188(6):1165-1173. doi: 10.1093/aje/kwz026.
129. Giunchi F, **Fiorentino M**, Loda M. The Metabolic Landscape of Prostate Cancer. *Eur Urol Oncol*. 2019 Feb;2(1):28-36. doi: 10.1016/j.euo.2018.06.010.

130. Urbini M, Indio V, Tarantino G, Ravegnini G, Angelini S, Nannini M, Saponara M, Santini D, Ceccarelli C, Fiorentino M, Vincenzi B, Fumagalli E, Casali PG, Grignani G, Pession A, Ardizzoni A, Astolfi A, Pantaleo MA. Gain ofFGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GIST. *Genes Chromosomes Cancer*. 2019 Sep;58(9):636-642. doi: 10.1002/gcc.22753.
131. Capizzi E, Ricci C, Giunchi F, Zagnoni S, Ceccarelli C, Gómez BUÁ, Casolari L, Gelsomino F, Trisolini R, **Fiorentino M**, Ardizzoni A. Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer. *Lung Cancer*. 2018 Dec;126:9-14. doi: 10.1016/j.lungcan.2018.10.017.
132. Carlsson J, Davidsson S, Fridfeldt J, Giunchi F, Fiano V, Grasso C, Zelic R, Richiardi L, Andrén O, Pettersson A, **Fiorentino M**, Akre O. Quantity and quality of nucleic acids extracted from archival formalin fixed paraffin embedded prostate biopsies. *BMC Med Res Methodol*. 2018 Dec 5;18(1):161. doi: 10.1186/s12874-018-0628-1.
133. Ambrosi F, **Fiorentino M**, Chessa F, Brunocilla E, D'Errico A, Bertuzzo RV, Giunchi F. Persistent Mullerian duct syndrome: Report of two cases with phenotypical immunohistochemical profiling. *Urologia*. 2018 Nov;85(4):177-181. doi: 10.1177/0391560317749426.
134. Ricci C, Rossi MS, De Stefano R, **Fiorentino M**, Vasuri F. Unusual metastatic localization to the kidney of basaloid squamous cell carcinoma of the oropharynx. *Urologia*. 2018 Nov;85(4):182-185. doi: 10.1177/0391560317749423.
135. Giunchi F, Cimadamore A, **Fiorentino M**. Emerging Molecular Technologies in Genitourinary Tumors. *Front Oncol*. 2018 Oct 30;8:489. doi: 10.3389/fonc.2018.00489.
136. Pernar CH, Ebot EM, Pettersson A, Graff RE, Giunchi F, Ahearn TU, Gonzalez- Feliciano AG, Markt SC, Wilson KM, Stopsack KH, Gazeeva E, Lis RT, Parmigiani G, Rimm EB, Finn SP, Giovannucci EL, **Fiorentino M**, Mucci LA. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG. *Eur Urol*. 2019 Jul;76(1):33-40. doi: 10.1016/j.eururo.2018.09.041.
137. Rihawi K, Alfieri R, **Fiorentino M**, Fontana F, Capizzi E, Cavazzoni A, Terracciano M, La Monica S, Ferrarini A, Buson G, Petronini PG, Ardizzoni A. MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report. *Transl Oncol*. 2019 Jan;12(1):116-121. doi: 10.1016/j.tranon.2018.09.013.
138. Isidori F, Malvi D, Fittipaldi S, Forcato C, Bozzarelli I, Sala C, Raulli G, D'Errico A, **Fiorentino M**, Seri M, Krishnadath KK, Bonora E, Mattioli S; EAC- BAGH group. Genomic profiles of primary and metastatic esophageal adenocarcinoma identified via digital sorting of pure cell populations: results from a case report. *BMC Cancer*. 2018 Sep 12;18(1):889. doi: 10.1186/s12885-018-4789-4.
139. Ahearn TU, Peisch S, Pettersson A, Ebot EM, Zhou CK, Graff RE, Sinnott JA, Fazli L, Judson GL, Bismar TA, Rider JR, Gerke T, Chan JM, Fiorentino M, Flavin R, Sesso HD, Finn S, Giovannucci EL, Gleave M, Loda M, Li Z, Pollak M, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP). Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. *Carcinogenesis*. 2018 Dec 31;39(12):1431-1437. doi: 10.1093/carcin/bgy112.
140. Di Nunno V, Cimadamore A, Santoni M, Scarpelli M, **Fiorentino M**, Ciccarese C, Iacovelli R, Cheng L, Lopez-Beltran A, Massari F, Montironi R. Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration- resistant prostate cancer. *Future Oncol*. 2018 Oct;14(25):2559-2564. doi:10.2217/fon-2018-0158.
141. DuPre NC, Flavin R, Sfanos KS, Unger RH, To S, Gazeeva E, **Fiorentino M**, De Marzo AM, Rider JR, Mucci LA; Transdisciplinary Prostate Cancer Partnership(ToPCaP). Corpora amylacea in prostatectomy tissue and associations with molecular, histological, and lifestyle factors. *Prostate*. 2018 Nov;78(15):1172-1180. doi: 10.1002/pros.23692.

142. Vasuri F, Visani M, Acquaviva G, Brand T, **Fiorentino M**, Pession A, Tallini G, D'Errico A, de Biase D. Role of microRNAs in the main molecular pathways of hepatocellular carcinoma. *World J Gastroenterol*. 2018 Jul 7;24(25):2647-2660. doi: 10.3748/wjg.v24.i25.2647.
143. Grabowska B, Ulvskog E, Carlsson J, **Fiorentino M**, Giunchi F, Lindblad P, Sundqvist P. Clinical outcome and time trends of surgically treated renal cell carcinoma between 1986 and 2010: results from a single centre in Sweden. *Scand J Urol*. 2018 Jun;52(3):206-212. doi: 10.1080/21681805.2018.1430706.
144. Graff RE, Ahearn TU, Pettersson A, Ebot EM, Gerke T, Penney KL, Wilson KM, Markt SC, Pernar CH, Gonzalez-Feliciano AG, Song M, Lis RT, Schmidt DR, Vander Heiden MG, **Fiorentino M**, Giovannucci EL, Loda M, Mucci LA. Height, Obesity, and the Risk of *TMPRSS2:ERG*-Defined Prostate Cancer. *Cancer Epidemiol Biomarkers Prev*. 2018 Feb;27(2):193-200. doi: 10.1158/1055-9965.EPI-17-0547.
145. Mollica V, Di Nunno V, Corcioni B, **Fiorentino M**, Nobili E, Schiavina R, Golfieri R, Brunocilla E, Ardizzoni A, Massari F. A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. *Anticancer Drugs*. 2018 Oct;29(9):911-913. doi: 10.1097/CAD.0000000000000663.
146. Cimadamore A, Gasparrini S, Santoni M, Cheng L, Lopez-Beltran A, Battelli N, Massari F, Giunchi F, **Fiorentino M**, Scarpelli M, Montironi R. Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. *Expert Rev Mol Diagn*. 2018 Jul;18(7):645-655. doi: 10.1080/14737159.2018.1490179.
147. Schiavina R, Bianchi L, Mineo Bianchi F, Borghesi M, Pultrone CV, Dababneh H, Castellucci P, Ceci F, Nanni C, Gaudiano C, **Fiorentino M**, Porreca A, Chessa F, Minervini A, Fanti S, Brunocilla E. Preoperative Staging With 11C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. *Clin Genitourin Cancer*. 2018 Aug;16(4):305-312.e1. doi: 10.1016/j.clgc.2018.05.010.
148. Di Nunno V, Mollica V, Corcioni B, **Fiorentino M**, Nobili E, Schiavina R, Golfieri R, Brunocilla E, Ardizzoni A, Massari F. Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. *Anticancer Drugs*. 2018 Aug;29(7):710-715. doi: 10.1097/CAD.0000000000000644.
149. Vasuri F, Fittipaldi S, De Pace V, Gramantieri L, Bertuzzo V, Cescon M, Pinna AD, **Fiorentino M**, D'Errico A, Ravaioli M. Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas. *Oncotarget*. 2018 Apr 3;9(25):17895-17905. doi: 10.18632/oncotarget.24860.
150. Martini S, Rizzello A, Corsini I, Romanin B, **Fiorentino M**, Grandi S, Bergamaschi R. Vitamin A Deficiency Due to Selective Eating as a Cause of Blindness in a High-Income Setting. *Pediatrics*. 2018 Apr;141(Suppl 5):S439-S444. doi: 10.1542/peds.2016-2628.
151. Indio V, Astolfi A, Tarantino G, Urbini M, Patterson J, Nannini M, Saponara M, Gatto L, Santini D, do Valle IF, Castellani G, Remondini D, **Fiorentino M**, von Mehren M, Brandi G, Biasco G, Heinrich MC, Pantaleo MA. Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. *Int J Mol Sci*. 2018 Mar 4;19(3):732. doi: 10.3390/ijms19030732.
152. Rihawi K, Cinausero M, **Fiorentino M**, Salvagni S, Brocchi S, Ardizzoni A. Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins. *J Thorac Oncol*. 2018 Mar;13(3):e41-e43. doi: 10.1016/j.jtho.2017.10.024.
153. Massari F, Di Nunno V, Comito F, Cubelli M, Ciccarese C, Iacovelli R, **Fiorentino M**, Montironi R, Ardizzoni A. Circulating tumor cells in genitourinary tumors. *Ther Adv Urol*. 2017 Nov 22;10(2):65-77. doi: 10.1177/1756287217742564.
154. Massari F, Di Nunno V, Cubelli M, Santoni M, **Fiorentino M**, Montironi R, Cheng L, Lopez-Beltran A, Battelli N, Ardizzoni A. Immune checkpoint inhibitors for metastatic bladder cancer. *Cancer Treat Rev*. 2018 Mar;64:11-20. doi:10.1016/j.ctrv.2017.12.007.
155. Schiavina R, Bianchi L, Borghesi M, Dababneh H, Chessa F, Pultrone CV, Angiolini A, Gaudiano C, Porreca A, **Fiorentino M**, De Groote R, D'Hondt F, De Naeyer G, Mottrie A, Brunocilla E. MRI Displays the

156. Serra C, Rizzello F, Pratico C, Felicani C, Fiorini E, Brugnera R, Mazzotta E, Giunchi F, **Fiorentino M**, D'Errico A, Morselli-Labate AM, Mastroberoberto M, Campieri M, Poggioli G, Gionchetti P. Real-time elastography for the detection of fibrotic and inflammatory tissue in patients with stricturing Crohn's disease. J Ultrasound. 2017 Oct 26;20(4):273-284. doi:10.1007/s40477-017-0265-2.
157. Graff RE, Ahearn TU, Pettersson A, Ebot EM, Gerke T, Penney KL, Wilson KM, Markt SC, Pernar CH, Gonzalez-Feliciano AG, Song M, Lis RT, Schmidt DR, Vander Heiden MG, **Fiorentino M**, Giovannucci EL, Loda M, Mucci LA. Height, Obesity, and the Risk of *TPRS2:ERG*-Defined Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):193-200. doi: 10.1158/1055-9965.EPI-17-0547.
158. Campana D, Walter T, Pusceddu S, Gelsomino F, Graillot E, Prinzi N, Spallanzani A, **Fiorentino M**, Barritault M, Dall'Olio F, Brighi N, Biasco G. Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. Endocrine. 2018 Jun;60(3):490-498. doi: 10.1007/s12020-017-1474-3.
159. Schiavina R, Bianchi L, Mineo Bianchi F, Borghesi M, Pultrone CV, Dababneh H, Castellucci P, Ceci F, Nanni C, Gaudiano C, **Fiorentino M**, Porreca A, Chessa F, Minervini A, Fanti S, Brunocilla E. Preoperative Staging With ¹¹C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. Clin Genitourin Cancer. 2018 Aug;16(4):305-312.e1. doi: 10.1016/j.clgc.2018.05.010.
160. Davidsson S, Andren O, Ohlson AL, Carlsson J, Andersson SO, Giunchi F, Rider JR, **Fiorentino M**. FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer. Prostate. 2018 Jan;78(1):40-47. doi: 10.1002/pros.23442.
161. Rostami K, Marsh MN, Johnson MW, Mohaghegh H, Heal C, Holmes G, Ensari A, Aldulaimi D, Bancel B, Bassotti G, Bateman A, Becheanu G, Bozzola A, Carroccio A, Catassi C, Ciacci C, Ciobanu A, Danciu M, Derakhshan MH, Elli L, Ferrero S, **Fiorentino M**, Fiorino M, Ganji A, Ghaffarzadehgan K, Going JJ, Ishaq S, Mandolesi A, Mathews S, Maxim R, Mulder CJ, Neefjes-Borst A, Robert M, Russo I, Rostami-Nejad M, Sidoni A, Sotoudeh M, Villanacci V, Volta U, Zali MR, Srivastava A. ROC-king onwards: intraepithelial lymphocyte counts, distribution & role in coeliac disease mucosal interpretation. Gut. 2017 Dec;66(12):2080-2086. doi: 10.1136/gutjnl-2017-314297.
162. Tyekucheva S, Bowden M, Bango C, Giunchi F, Huang Y, Zhou C, Bondi A, Lis R, Van Hemelrijck M, Andr n O, Andersson SO, Watson RW, Pennington S, Finn SP, Martin NE, Stampfer MJ, Parmigiani G, Penney KL, **Fiorentino M**, Mucci LA, Loda M. Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nat Commun. 2017 Sep 4;8(1):420. doi: 10.1038/s41467-017-00460-4.
163. Livi V, Ardizzoni A, Cancellieri A, Natali F, Ferrari M, Paioli D, De Biase D, Capizzi E, Tallini G, **Fiorentino M**, Trisolini R. Adequacy of endosonography-derived samples from peribronchial or periesophageal intrapulmonary lesions for the molecular profiling of lung cancer. Clin Respir J. 2019 Sep;13(9):590-597. doi: 10.1111/crj.13063. Epub 2019 Aug 9.
164. Rihawi K, Gelsomino F, Sperandi F, Melotti B, **Fiorentino M**, Casolari L, Ardizzoni A. Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence. Ther Adv Respir Dis. 2017 Sep;11(9):353-373. doi: 10.1177/1753465817725486.
165. Massari F, Ciccarese C, Hes O, Michal M, Cal   A, **Fiorentino M**, Giunchi F, D'Amuri A, Sanguedolce F, Sabbatini R, Guida A, Ardizzoni A, Porta C, Iacovelli R, Tortora G, Cima L, Ortega C, Lapini A, Martignoni G, Brunelli M. The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. Pathol Oncol Res. 2018 Jul;24(3):447-456. doi: 10.1007/s12253-017-0271-x.
166. Adua D, Di Fabio F, Ercolani G, **Fiorentino M**, Gruppioni E, Altimari A, Rojas Limpe FL, Normanno N, Pinna AD, Pinto C. Heterogeneity in the colorectal primary tumor and the synchronous resected liver

metastases prior to and after treatment with an anti-EGFR monoclonal antibody. *Mol Clin Oncol*. 2017 Jul;7(1):113-120. doi: 10.3892/mco.2017.1270.

167. Dika E, Fanti PA, Vaccari S, Capizzi E, Degiovanni A, Gobbi A, Piraccini BM, Ribero S, Baraldi C, Ravaoli GM, **Fiorentino M**, Patrizi A. Oestrogen and progesterone receptors in melanoma and nevi: an immunohistochemical study. *Eur J Dermatol*. 2017 Jun 1;27(3):254-259. doi: 10.1684/ejd.2017.3019. PMID: 28524047.
168. Ciccarese C, Montironi R, **Fiorentino M**, Martignoni G, Brunelli M, Iacovelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Moch H, Tortora G, Massari F. Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment? *Curr Drug Metab*. 2017;18(8):692-699. doi: 10.2174/1389200218666170518163549.
169. Giunchi F, Ciccarese C, Montironi R, Scarpelli M, Lopez-Beltran A, Cheng L, Moch H, Massari F, **Fiorentino M**. Urinary Biomarkers for Prostate Cancer. *Curr Drug Metab*. 2017 Oct 16;18(8):723-726. doi: 10.2174/1389200218666170518161140.
170. Mann SA, Lopez-Beltran A, Massari F, Pili R, **Fiorentino M**, Koch MO, Kaimakliotis HZ, Wang L, Scarpelli M, Ciccarese C, Moch H, Montironi R, Cheng L. Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. *Curr Drug Metab*. 2017 Oct 16;18(8):700-711. doi: 10.2174/1389200218666170518162500.
171. Blanca A, Cheng L, Montironi R, Moch H, Massari F, **Fiorentino M**, Raspollini MR, Scarpelli M, Lopez-Beltran A. Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice. *Curr Drug Metab*. 2017 Oct 16;18(8):712-722. doi: 10.2174/1389200218666170518164507.
172. Giunchi F, Vasuri F, Valerio V, Montagnani I, Nelli F, **Fiorentino M**, Raspollini MR. Unusual asymptomatic presentation of bladder cancer metastatic to the penis. *Pathol Res Pract*. 2017 Jun;213(6):717-720. doi:10.1016/j.prp.2016.11.019.
173. Giunchi F, Jordahl K, Bollito E, Colecchia M, Patriarca C, D'Errico A, Vasuri F, Malvi D, Fornari A, Bonetti LR, Corti B, Papotti M, DeGiuli P, Loda M, Montironi R, **Fiorentino M**, Rider JR. Interpathologist concordance in the histological diagnosis of focal prostatic atrophy lesions, acute and chronic prostatitis, PIN, and prostate cancer. *Virchows Arch*. 2017 Jun;470(6):711-715. doi: 10.1007/s00428-017-2123-1.
174. Ciccarese C, Massari F, Iacovelli R, **Fiorentino M**, Montironi R, Di Nunno V, Giunchi F, Brunelli M, Tortora G. Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. *Cancer Treat Rev*. 2017 Mar;54:68-73. doi:10.1016/j.ctrv.2017.02.001.
175. Agostinelli C, Carloni S, Limarzi F, Righi S, Laginestra MA, Musuraca G, **Fiorentino M**, Napolitano R, Cuneo A, Vergara D, Zinzani PL, Sabattini E, Pileri SA, De Matteis S. The emerging role of GSK-3 β in the pathobiology of classical Hodgkin lymphoma. *Histopathology*. 2017 Jul;71(1):72-80. doi: 10.1111/his.13189.
176. Zuntini R, Cortesi L, Calistri D, Pippucci T, Martelli PL, Casadio R, Capizzi E, Santini D, Miccoli S, Medici V, Danesi R, Marchi I, Zampiga V, **Fiorentino M**, Ferrari S, Turchetti D. BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype. *Oncotarget*. 2017 Apr 4;8(14):22640-22648. doi: 10.18632/oncotarget.15151.
177. Fandella A, Scattoni V, Galosi A, Pepe P, **Fiorentino M**, Gaudiano C, Giampaoli M, Gunelli R, Martino P, Montanaro V, Montironi R, Pierangeli T, Stabile A, Bertaccini A. Italian Prostate Biopsies Group: 2016 Updated Guidelines Insights. *Anticancer Res*. 2017 Feb;37(2):413-424. doi: 10.21873/anticancer.11333.
178. Graff RE, Judson G, Ahearn TU, **Fiorentino M**, Loda M, Giovannucci EL, Mucci LA, Pettersson A. Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG. *Prostate*. 2017 May;77(6):647-653. doi: 10.1002/pros.23312.
179. Zareba P, Flavin R, Isikbay M, Rider JR, Gerke TA, Finn S, Pettersson A, Giunchi F, Unger RH, Tinianow AM, Andersson SO, Andr  n O, Fall K, **Fiorentino M**, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP). Perineural Invasion and Risk of Lethal Prostate Cancer. *Cancer Epidemiol Biomarkers Prev*. 2017 May;26(5):719-726. doi: 10.1158/1055-9965.EPI-16-0237.

180. **Fiorentino M**, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R. Considerations for standardizing predictive molecular pathology for cancer prognosis. *Expert Rev Mol Diagn.* 2017 Jan;17(1):47-55. doi: 10.1080/14737159.2017.1266258.
181. Ceci F, **Fiorentino M**, Castellucci P, Fanti S. Molecular Imaging and Precision Medicine in Prostate Cancer. *PET Clin.* 2017 Jan;12(1):83-92. doi: 10.1016/j.cpet.2016.08.004.
182. Giunchi F, Degiovanni A, Daddi N, Trisolini R, Dell'Amore A, Agostinelli C, Ardizzoni A, **Fiorentino M**. Fading With Time of PD-L1 Immunoreactivity in Non- Small Cells Lung Cancer Tissues: A Methodological Study. *Appl Immunohistochem Mol Morphol.* 2018 Aug;26(7):489-494. doi: 10.1097/PAI.0000000000000458.
183. Giunchi F, Vasuri F, Colecchia M, Gentile G, Garofalo M, Schiavina R, **Fiorentino M**. Frozen section analysis of unusual small testicular tumor masses:report of 3 cases. *Tumori.* 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000477.
184. **Fiorentino M**, Gruppioni E, Massari F, Giunchi F, Altimari A, Ciccarese C, Bimbatti D, Scarpa A, Iacovelli R, Porta C, Virinder S, Tortora G, Artibani W, Schiavina R, Ardizzoni A, Brunelli M, Knuutila S, Martignoni G. Wide spetcrummutational analysis of metastatic renal cell cancer: a retrospective nextgeneration sequencing approach. *Oncotarget.* 2017 Jan 31;8(5):7328-7335. doi:10.18632/oncotarget.12551.
185. Sinnott JA, Peisch SF, Tyekucheva S, Gerke T, Lis R, Rider JR, **Fiorentino M**, Stampfer MJ, Mucci LA, Loda M, Penney KL. Prognostic Utility of a New mRNA Expression Signature of Gleason Score. *Clin Cancer Res.* 2017 Jan 1;23(1):81-87. doi: 10.1158/1078-0432.CCR-16-1245.
186. Modena A, Ciccarese C, Iacovelli R, Brunelli M, Montironi R, **Fiorentino M**, Tortora G, Massari F. Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? *Oncol Rev.* 2016 Apr 15;10(1):293. doi: 10.4081/oncol.2016.293.
187. Ciccarese C, Brunelli M, Montironi R, **Fiorentino M**, Iacovelli R, Heng D, Tortora G, Massari F. The prospect of precision therapy for renal cell carcinoma. *Cancer Treat Rev.* 2016 Sep;49:37-44. doi: 10.1016/j.ctrv.2016.07.003. Epub 2016 Jul 12. PMID: 27453294.
188. Yang M, Zu K, Mucci LA, Rider JR, **Fiorentino M**, Clinton SK, Loda M, Stampfer MJ, Giovannucci E. Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade. *Cancer Causes Control.* 2016 Aug;27(8):1043-7. doi: 10.1007/s10552-016-0782-x.
189. Giunchi F, **Fiorentino M**, Vagnoni V, Capizzi E, Bertolo R, Porpiglia F, Vatrano S, Tamberi S, Schiavina R, Papotti M, Bollito E. Renal oncocytosis: a clinicopathological and cytogenetic study of 42 tumours occurring in 11 patients. *Pathology.* 2016 Jan;48(1):41-6. doi: 10.1016/j.pathol.2015.11.009.
190. Graff RE, Meisner A, Ahearn TU, **Fiorentino M**, Loda M, Giovannucci EL, Mucci LA, Pettersson A. Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression. *Br J Cancer.* 2016 Apr 12;114(8):939-44. doi: 10.1038/bjc.2016.61.
191. Giunchi F, Panzacchi R, Capizzi E, Schiavina R, Brunocilla E, Martorana G, D'Errico A, **Fiorentino M**. Role of Inter-Observer Variability and Quantification of Muscularis Propria in the Pathological Staging of Bladder Cancer. *Clin Genitourin Cancer.* 2016 Aug;14(4):e307-12. doi: 10.1016/j.clgc.2016.01.002.
192. Graff RE, Pettersson A, Lis RT, Ahearn TU, Markt SC, Wilson KM, Rider JR, **Fiorentino M**, Finn S, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Mucci LA. Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. *Am J Clin Nutr.* 2016 Mar;103(3):851-60. doi: 10.3945/ajcn.115.118703.
193. Thorgeirsson T, Jordahl KM, Flavin R, Epstein MM, **Fiorentino M**, Andersson SO, Andren O, Rider JR, Mosquera JM, Ingoldsby H, Fall K, Tryggvadottir L, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP). Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort. *Carcinogenesis.* 2016 Mar;37(3):262-8. doi: 10.1093/carcin/bgw001.
194. Barbaro MR, Di Sabatino A, Cremon C, Giuffrida P, **Fiorentino M**, Altimari A, Bellacosa L, Stanghellini V, Barbara G. Interferon- γ is increased in the gut of patients with irritable bowel syndrome and modulates

serotonin metabolism. *Am J Physiol Gastrointest Liver Physiol*. 2016 Mar 15;310(6):G439-47. doi: 10.1152/ajpgi.00368.2015.

195. Saponara M, Gatto L, Di Nunno V, Tabacchi E, Fanti S, Di Scioscio V, Nannini M, Gruppioni E, Altimari A, **Fiorentino M**, Santini D, Ceccarelli C, Zompatori M, Biasco G, Pantaleo MA. Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors. *Anticancer Drugs*. 2016 Apr;27(4):353-63. doi: 10.1097/CAD.0000000000000331.
196. Garajová I, Funel N, **Fiorentino M**, Agostini V, Ferracin M, Negrini M, Frassinetti GL, Gavelli G, Frampton AE, Biasco G, Giovannetti E. MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy. *Clin Epigenetics*. 2015 Dec 16;7:129. doi: 10.1186/s13148-015-0162-5.
197. Farina E, Monari F, Tallini G, Repaci A, Mazzarotto R, Giunchi F, Panzacchi R, Cammelli S, Padula GD, Deodato F, Pasquali R, Fanti S, **Fiorentino M**, Morganti AG. Unusual Thyroid Carcinoma Metastases: a Case Series and Literature Review. *Endocr Pathol*. 2016 Mar;27(1):55-64. doi: 10.1007/s12022-015-9410-7.
198. Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, **Fiorentino M**, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. *J Natl Cancer Inst*. 2015 Nov 27;108(2):djv346. doi: 10.1093/jnci/djv346. PMID: 26615022; PMCID: PMC4862436.
199. Saponara M, Urbini M, Astolfi A, Indio V, Ercolani G, Del Gaudio M, Santini D, Pirini MG, **Fiorentino M**, Nannini M, Lolli C, Mandrioli A, Gatto L, Brandi G, Biasco G, Pinna AD, Pantaleo MA. Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFR α genotype evaluated by next generation sequencing (NGS). *Oncotarget*. 2015 Dec 8;6(39):42243-57. doi: 10.18632/oncotarget.6278.
200. Zanirato Rambaldi G, Monari F, **Fiorentino M**, Cammelli S, Repaci A, Cremonini N, Cavicchi O, Caliceti U, Farina E, Deodato F, Di Fabio F, Presutti L, Fanti S, Frezza GP, Morganti AG. Complete pathological response after chemo-radiation in anaplastic thyroid cancer: A report of two cases. *Acta Oncol*. 2016;55(4):530-2. doi: 10.3109/0284186X.2015.1102966.
201. Lu D, Sinnott JA, Valdimarsdóttir U, Fang F, Gerke T, Tyekucheva S, **Fiorentino M**, Lambe M, Sesso HD, Sweeney CJ, Wilson KM, Giovannucci EL, Loda M, Mucci LA, Fall K. Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer. *Clin Cancer Res*. 2016 Feb 1;22(3):765-772. doi: 10.1158/1078-0432.CCR-15-0101.
202. Schiavina R, Borghesi M, Chessa F, Dababneh H, Bianchi L, Della Mora L, Del Prete C, Longhi B, Rizzi S, **Fiorentino M**, Martorana G, Brunocilla E. The Prognostic Impact of Tumor Size on Cancer-Specific and Overall Survival Among Patients With Pathologic T3a Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2015 Aug;13(4):e235-e241. doi: 10.1016/j.clgc.2014.06.011.
203. Barbareschi M, Barberis M, Buttitta F, Doglioni C, **Fiorentino M**, Fontanini G, Franco R, Marchetti A, Rossi G, Troncone G. Predictive markers in lung cancer: a few hints for the practicing pathologist. *Pathologica*. 2018 Mar;110(1):29-38.
204. Martin NE, Gerke T, Sinnott JA, Stack EC, Andrén O, Andersson SO, Johansson JE, **Fiorentino M**, Finn S, Fedele G, Stampfer M, Kantoff PW, Mucci LA, Loda M. Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. *Mol Cancer Res*. 2015 Oct;13(10):1431-40. doi: 10.1158/1541-7786.MCR-14-0569.
205. Tyekucheva S, Martin NE, Stack EC, Wei W, Vathipadiekal V, Waldron L, **Fiorentino M**, Lis RT, Stampfer MJ, Loda M, Parmigiani G, Mucci LA, Birrer M. Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. *J Mol Diagn*. 2015 Jul;17(4):374-81. doi: 10.1016/j.jmoldx.2015.02.002.
206. Dika E, Fanti PA, **Fiorentino M**, Capizzi E, Neri I, Piraccini BM, Ravaioli GM, Misciali C, Passarini B, Patrizi A. Spitzoid tumors in children and adults: a comparative clinical, pathological, and cytogenetic analysis. *Melanoma Res*. 2015 Aug;25(4):295-301. doi: 10.1097/CMR.0000000000000160.

207. Rider JR, **Fiorentino M**, Kelly R, Gerke T, Jordahl K, Sinnott JA, Giovannucci EL, Loda M, Mucci LA, Finn S; Transdisciplinary Prostate Cancer Partnership (ToPCaP). Tumor expression of adiponectin receptor 2 and lethal prostate cancer. *Carcinogenesis*. 2015 Jun;36(6):639-47. doi: 10.1093/carcin/bgv048.
208. Ceci F, **Fiorentino M**, Castellucci P, Fanti S. Molecular Imaging and Precision Medicine in Prostate Cancer. *PET Clin*. 2017 Jan;12(1):83-92. doi: 10.1016/j.cpet.2016.08.004.
209. Graff RE, Pettersson A, Lis RT, DuPre N, Jordahl KM, Nuttall E, Rider JR, **Fiorentino M**, Sesso HD, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Nguyen PL, Sweeney CJ, Mucci LA; Transdisciplinary Prostate Cancer Partnership ToPCaP. The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer. *Prostate*. 2015 Jun 15;75(9):897-906. doi: 10.1002/pros.22973.
210. Vasuri F, Malvi D, Rosini F, Baldin P, **Fiorentino M**, Paccapelo A, Ercolani G, Pinna AD, Golfieri R, Morselli-Labate AM, Grigioni WF, D'Errico-Grigioni A. Revisiting the role of pathological analysis in transarterial chemoembolization-treated hepatocellular carcinoma after transplantation. *World J Gastroenterol*. 2014 Oct 7;20(37):13538-45. doi: 10.3748/wjg.v20.i37.13538.
211. Schiavina R, Capizzi E, Borghesi M, Vagnoni V, Romagnoli D, Rocca GC, Giunchi F, D'Errico A, De Giovanni A, Rizzi S, Brunocilla E, Martorana G, **Fiorentino M**. Nodal occult metastases in intermediate- and high-risk prostate cancer patients detected using serial section, immunohistochemistry, and real-time reverse transcriptase polymerase chain reaction: prospective evaluation with matched-pair analysis. *Clin Genitourin Cancer*. 2015 Apr;13(2):e55-64. doi: 10.1016/j.clgc.2014.08.004.
212. Dika E, Patrizi A, Altimari A, **Fiorentino M**, La Placa M, Gruppioni E, Venturoli S, Vaccari S, Melotti B, Piraccini BM, Fanti PA. Virologic and genetic evaluation of vemurafenib-induced skin cancers. *Cutan Ocul Toxicol*. 2015;34(3):251-3. doi: 10.3109/15569527.2014.949345.
213. Pantaleo MA, Lolli C, Nannini M, Astolfi A, Indio V, Saponara M, Urbini M, La Rovere S, Gill A, Goldstein D, Ceccarelli C, Santini D, Rossi G, **Fiorentino M**, Di Scioscio V, Fusaroli P, Mandrioli A, Gatto L, Catena F, Basso U, Ercolani G, Pinna AD, Biasco G. Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. *Genet Med*. 2015 May;17(5):391-5. doi: 10.1038/gim.2014.115.
214. Malvi D, Vasuri F, Mattioli B, Gruppioni E, **Fiorentino M**, Gionchetti P, Grigioni WF, Poggioli G, D'Errico-Grigioni A. Adenocarcinoma in Crohn's disease: the pathologist's experience in a tertiary referral centre of inflammatory bowel disease. *Pathology*. 2014 Aug;46(5):439-43. doi: 10.1097/PAT.0000000000000123.
215. Flavin R, Pettersson A, Hendrickson WK, **Fiorentino M**, Finn S, Kunz L, Judson GL, Lis R, Bailey D, Fiore C, Nuttall E, Martin NE, Stack E, Penney KL, Rider JR, Sinnott J, Sweeney C, Sesso HD, Fall K, Giovannucci E, Kantoff P, Stampfer M, Loda M, Mucci LA. SPINK1 protein expression and prostate cancer progression. *Clin Cancer Res*. 2014 Sep 15;20(18):4904-11. doi: 10.1158/1078-0432.CCR-13-1341.
216. **Fiorentino M**, Giunchi F, Altimari A, Di Tullio P, Gruppioni E, Martorana G, Pinto C. Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations. *Oncologist*. 2014 Apr;19(4):430. doi:10.1634/theoncologist.2013-0346.
217. Fuccio L, Correale L, Arezzo A, Repici A, Manes G, Trovato C, Mangiavillano B, Manno M, Cortelezzi CC, Dinelli M, Cennamo V, de Bellis M; Altimari A, Cariani G, Caruso A, Conigliaro RCrosta C, Delrio P, Di Marco MC, Fabbri C, **Fiorentino M**, Gherzi S, Gruppioni E, Hassan C, Laterza L, Nasti G, Pinto C, Rojas F. Influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: a retrospective multicentre study. *Dig Liver Dis*. 2014 Jun;46(6):561-7. doi: 10.1016/j.dld.2014.02.006.
218. Giunchi F, Brunocilla E, Borghesi M, Rizzi S, Ricci MS, Romagnoli D, Martorana G, Schiavina R, **Fiorentino M**. Revised Gleason grading system is a better predictor of indolent prostate cancer at the time of diagnosis: retrospective clinical-pathological study on matched biopsy and radical prostatectomy specimens. *Clin Genitourin Cancer*. 2014 Oct;12(5):325-9. doi: 10.1016/j.clgc.2014.01.009.
219. Brunocilla E, Ceci F, Schiavina R, Castellucci P, Maffione AM, Cevenini M, Bianchi L, Borghesi M, Giunchi F, **Fiorentino M**, Chondrogiannis S, Colletti PM, Rubello D, Fanti S, Martorana G. Diagnostic accuracy of (11)C-choline PET/CT in preoperative lymph node staging of bladder cancer: a systematic comparison with contrast-

enhanced CT and histologic findings. Clin Nucl Med. 2014 May;39(5):e308-12. doi: 10.1097/RLU.0000000000000342.

220. Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, **Fiorentino M**, Finn S, Graff RE, Penney KL, Rider JR, Nuttall EJ, Martin NE, Sesso HD, Pollak M, Stampfer MJ, Kantoff PW, Giovannucci EL, Loda M, Mucci LA. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst. 2013 Dec 18;105(24):1881-90. doi: 10.1093/jnci/djt332.
221. Kasperzyk JL, Finn SP, Flavin R, **Fiorentino M**, Lis R, Hendrickson WK, Clinton SK, Sesso HD, Giovannucci EL, Stampfer MJ, Loda M, Mucci LA. Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2354-63. doi: 10.1158/1055-9965.EPI-13-0668.
222. Storci G, Bertoni S, De Carolis S, Papi A, Nati M, Ceccarelli C, Pirazzini C, Garagnani P, Ferrarini A, Buson G, Delledonne M, **Fiorentino M**, Capizzi E, Gruppioni E, Taffurelli M, Santini D, Franceschi C, Bandini G, Bonifazi F, Bonafé M. Slug/ β -catenin-dependent proinflammatory phenotype in hypoxic breast cancer stem cells. Am J Pathol. 2013 Nov;183(5):1688-1697. doi:10.1016/j.ajpath.2013.07.020.
223. Ciccarese C, Di Nunno V, Montironi R, **Fiorentino M**, Brunelli M, Tortora G, Massari F The role of precision medicine for the treatment of metastatic renal cell carcinoma. Expert review of precision medicine and drug development. 2016; 1:369-377. 10.1080/23808993.2016.1214057
224. Sanchez A, Schoenfeld JD, Nguyen PL, **Fiorentino M**, Chowdhury D, Stampfer MJ, Sesso HD, Giovannucci E, Mucci LA, Shui IM. Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment. Prostate Cancer Prostatic Dis. 2016 Jun;19(2):197-201. doi: 10.1038/pcan.2016.4. Epub 2016 Mar 1.
225. Schiavina R, Borghesi M, Brunocilla E, Romagnoli D, Diazi D, Giunchi F, Vagnoni V, Pultrone CV, Dababneh H, Porreca A, **Fiorentino M**, Martorana G. The biopsy Gleason score 3+4 in a single core does not necessarily reflect an unfavourable pathological disease after radical prostatectomy in comparison with biopsy Gleason score 3+3: looking for larger selection criteria for active surveillance candidates. Prostate Cancer Prostatic Dis. 2015 Sep;18(3):270-5. doi: 10.1038/pcan.2015.21.
226. Flavin R, Pettersson A, Hendrickson WK, **Fiorentino M**, Finn S, Kunz L, Judson GL, Lis R, Bailey D, Fiore C, Nuttall E, Martin NE, Stack E, Penney KL, Rider JR, Sinnott J, Sweeney C, Sesso HD, Fall K, Giovannucci E, Kantoff P, Stampfer M, Loda M, Mucci LA. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014 Sep 15;20(18):4904-11. doi: 10.1158/1078-0432.CCR-13-1341.
227. Zu K, Martin NE, **Fiorentino M**, Flavin R, Lis RT, Sinnott JA, Finn S, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci E. Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):1984-93. doi: 10.1158/1055-9965.EPI-13-0349.
228. Pantaleo MA, Astolfi A, Urbini M, Nannini M, Paterini P, Indio V, Saponara M, Formica S, Ceccarelli C, Casadio R, Rossi G, Bertolini F, Santini D, Pirini MG, **Fiorentino M**, Basso U, Biasco G; GIST Study Group. Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFR α wild-type GIST. Eur J Hum Genet. 2014 Jan;22(1):32-9. doi: 10.1038/ejhg.2013.80.
229. Altimari A, de Biase D, De Maglio G, Gruppioni E, Capizzi E, Degiovanni A, D'Errico A, Pession A, Pizzolitto S, **Fiorentino M**, Tallini G. 454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples. Onco Targets Ther. 2013 Aug 5;6:1057-64. doi: 10.2147/OTT.S42369.
230. Penney KL, Stampfer MJ, Jahn JL, Sinnott JA, Flavin R, Rider JR, Finn S, Giovannucci E, Sesso HD, Loda M, Mucci LA, **Fiorentino M**. Gleason grade progression is uncommon. Cancer Res. 2013 Aug 15;73(16):5163-8. doi:10.1158/0008-5472.CAN-13-0427.
231. Baccos A, Brunocilla E, Schiavina R, Borghesi M, Rocca GC, Chessa F, Saraceni G, **Fiorentino M**, Martorana G. Differing risk of cancer death among patients with pathologic T3a renal cell carcinoma:

identification of risk categories according to fat infiltration and renal vein thrombosis. Clin Genitourin Cancer. 2013 Dec;11(4):451-7. doi: 10.1016/j.clgc.2013.05.006.

232. Vagnoni V, Brunocilla E, Schiavina R, Borghesi M, Passaretti G, Gentile G, **Fiorentino M**, Martorana G. Inguinal canal tumors of adulthood. Anticancer Res. 2013 Jun;33(6):2361-8.
233. Schiavina R, Borghesi M, **Fiorentino M**, Brunocilla E, Manferrari F, Vagnoni V, Martorana G. Identification of prostate cancer risk categories according to surgical margins status, pathological stage and Gleason score. Int J Urol. 2013 Nov;20(11):1097-103. doi: 10.1111/iju.12124.
234. Fernandez IJ, Piccin O, Sciascia S, Cavicchi O, Repaci A, Vicennati V, **Fiorentino M**. Clinical significance of BRAF mutation in thyroid papillary cancer. Otolaryngol Head Neck Surg. 2013 Jun;148(6):919-25. doi: 10.1177/0194599813481942.
235. Schiavina R, Borghesi M, Brunocilla E, Manferrari F, **Fiorentino M**, Vagnoni V, Baccos A, Pultrone CV, Rocca GC, Rizzi S, Martorana G. Differing risk of cancer death among patients with lymph node metastasis after radical prostatectomy and pelvic lymph node dissection: identification of risk categories according to number of positive nodes and Gleason score. BJU Int. 2013 Jun;111(8):1237-44. doi: 10.1111/j.1464-410X.2012.11602.x.
236. Vasuri F, Morelli MC, Gruppioni E, **Fiorentino M**, Ercolani G, Cescon M, Pinna AD, Grigioni WF, D'Errico-Grigioni A. The meaning of tissue and serum HCV RNA quantitation in hepatitis C recurrence after liver transplantation: a retrospective study. Dig Liver Dis. 2013 Jun;45(6):505-9. doi: 10.1016/j.dld.2012.11.015.
237. Davidsson S, Ohlson AL, Andersson SO, Fall K, Meisner A, **Fiorentino M**, Andrén O, Rider JR. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer. Mod Pathol. 2013 Mar;26(3):448-55. doi: 10.1038/modpathol.2012.164.
238. Strillacchi A, Valerii MC, Sansone P, Caggiano C, Sgromo A, Vittori L, **Fiorentino M**, Poggioli G, Rizzello F, Campieri M, Spisni E. Loss of miR-101 expression promotes Wnt/ β -catenin signalling pathway activation and malignancy in colon cancer cells. J Pathol. 2013 Feb;229(3):379-89. doi: 10.1002/path.4097.
239. Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, Rider JR, Sweeney C, Stampfer MJ, **Fiorentino M**, Kantoff PW, Sanda MG, Giovannucci EL, Ding EL, Loda M, Mucci LA. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1497-509. doi: 10.1158/1055-9965.EPI-12-0042.
240. Dika E, Altimari A, Patrizi A, Gruppioni E, **Fiorentino M**, Piraccini BM, Misciali C, Barisani A, Fanti PA. KIT, NRAS, and BRAF mutations in nail apparatus melanoma. Pigment Cell Melanoma Res. 2013 Sep;26(5):758-60. doi: 10.1111/pcmr.12123.
241. Fiore C, Bailey D, Conlon N, Wu X, Martin N, **Fiorentino M**, Finn S, Fall K, Andersson SO, Andren O, Loda M, Flavin R. Utility of multispectral imaging in automated quantitative scoring of immunohistochemistry. J Clin Pathol. 2012 Jun;65(6):496-502. doi: 10.1136/jclinpath-2012-200734.
242. Baccos A, Schiavina R, Zukerman Z, Busato F, Gaudiano C, Salizzoni E, **Fiorentino M**, Golfieri R, Martorana G. Accuratezza della RMN 1,5 T con bobina endorettale e della RMN dinamica (DCE MRI) nella stadiazione preoperatoria dei pazienti affetti da carcinoma prostatico [Accuracy of endorectal Magnetic Resonance Imaging (MRI) and Dynamic Contrast Enhanced-MRI (DCE-MRI) in the preoperative local staging of prostate cancer]. Urologia. 2012 Apr-Jun;79(2):116-22. Italian. doi: 10.5301/RU.2012.9207.
243. Guarnieri V, Baorda F, Battista C, Bisceglia M, Balsamo T, Gruppioni E, **Fiorentino M**, Muscarella LA, Coco M, Barbano R, Corbetta S, Spada A, Cole DE, Canaff L, Hendy GN, Carella M, Scillitani A. A rare S33C mutation of CTNNB1 encoding β -catenin in a parathyroid adenoma found in an Italian primary hyperparathyroid cohort. Endocrine. 2012 Feb;41(1):152-5. doi:10.1007/s12020-011-9558-y.
244. Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, Stark JR, **Fiorentino M**, Perner S, Finn S, Calza S, Flavin R, Freedman ML, Setlur S, Sesso HD, Andersson SO, Martin N, Kantoff PW, Johansson JE, Adami

HO, Rubin MA, Loda M, Golub TR, Andrén O, Stampfer MJ, Mucci LA. mRNA expression signature of Gleason grade predicts lethal prostate cancer. *J Clin Oncol*. 2011 Jun 10;29(17):2391-6. doi: 10.1200/JCO.2010.32.6421.

245. Pantaleo MA, Nannini M, Saponara M, Gnocchi C, Di Scioscio V, Lolli C, Catena F, Astolfi A, Di Battista M, Biasco G; Altimari A, Castellucci P, Ceccarelli C, Fanti S, **Fiorentino M**, Formica S, Fusaroli P, Gatto L, Grigioni WF, Gruppioni E, Maleddu A, Mandrioli A, Pallotti C, Paterini P, Pinna AD, Santini D, Tomassetti P, Urbini M, Zompatori M. Impressive long-term disease stabilization by nilotinib in two pretreated patients with KIT/PDGFR α wild-type metastatic gastrointestinal stromal tumours. *Anticancer Drugs*. 2012 Jun;23(5):567-72. doi: 10.1097/CAD.0b013e328352cc50.
246. Pantaleo MA;Nannini M;Astolfi A;Biasco G;Altimari A; Castellucci P; Casadio R; Catena F; Ceccarelli C; Scioscio VD; **Fiorentino M**; Formica S; Fusaroli P; Indio V; Gatto L; Grigioni WF; Gruppioni E; Lolli C; Maleddu A; Mandrioli A; Martelli PL; Caterina Pallotti M; Paterini P; Daniele Pinna A; Santini D; Tomassetti P; Zompatori M; Urbini M.. A distinct pediatric-type gastrointestinal stromal tumor in adults: potential role of succinate dehydrogenase subunit A mutations. *Am J Surg Pathol*. 2011 Nov;35(11):1750-2. doi: 10.1097/PAS.0b013e318230a523.
247. Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollak M, **Fiorentino M**, Finn S, Loda M, Rifai N, Mucci LA, Giovannucci E, Stampfer MJ, Ma J. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. *Cancer Epidemiol Biomarkers Prev*. 2011 Dec;20(12):2618-27. doi: 10.1158/1055-9965.EPI-11-0434.
248. Davidsson S, **Fiorentino M**, Andrén O, Fang F, Mucci LA, Varenhorst E, Fall K, Rider JR. Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. *Cancer Epidemiol Biomarkers Prev*. 2011 Oct;20(10):2280-7. doi: 10.1158/1055-9965.EPI-11-0373.
249. Brunelli M, **Fiorentino M**, Gobbo S, Sperandio N, Cheng L, Cossu-Rocca P, Segala D, Eble JN, Delahunt B, Novara G, Ficarra V, Martignoni G. Many facets of chromosome 3p cytogenetic findings in clear cell renal carcinoma: the need for agreement in assessment FISH analysis to avoid diagnostic errors. *Histol Histopathol*. 2011 Sep;26(9):1207-13. doi: 10.14670/HH-26.1207.
250. Vasuri F, Golfieri R, **Fiorentino M**, Capizzi E, Renzulli M, Pinna AD, Grigioni WF, D'Errico-Grigioni A. OATP 1B1/1B3 expression in hepatocellular carcinomas treated with orthotopic liver transplantation. *Virchows Arch*. 2011 Aug;459(2):141-6. doi: 10.1007/s00428-011-1099-5.
251. Hendrickson WK, Flavin R, Kasperzyk JL, **Fiorentino M**, Fang F, Lis R, Fiore C, Penney KL, Ma J, Kantoff PW, Stampfer MJ, Loda M, Mucci LA, Giovannucci E. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. *J Clin Oncol*. 2011 Jun 10;29(17):2378-85. doi: 10.1200/JCO.2010.30.9880.
252. Flavin RJ, Cook J, **Fiorentino M**, Bailey D, Brown M, Loda MF. β -Catenin is a useful adjunct immunohistochemical marker for the diagnosis of pulmonary lymphangioleiomyomatosis. *Am J Clin Pathol*. 2011 May;135(5):776-82. doi: 10.1309/AJCP9EX1ZHMMA.
253. Nguyen PL, Ma J, Chavarro JE, Freedman ML, Lis R, Fedele G, Fiore C, Qiu W, **Fiorentino M**, Finn S, Penney KL, Eisenstein A, Schumacher FR, Mucci LA, Stampfer MJ, Giovannucci E, Loda M. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. *J Clin Oncol*. 2010 Sep1;28(25):3958-64. doi: 10.1200/JCO.2009.27.0793.
254. Nguyen PL, Lin DI, Lei J, **Fiorentino M**, Mueller E, Weinstein MH, Pagano M, Loda M. The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy. *Urol Oncol*. 2011 May-Jun;29(3):302-8. doi: 10.1016/j.urolonc.2009.03.022.
255. Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, **Fiorentino M**, Finn S, Flavin RJ, Kurth T, Price AL, Giovannucci EL, Fall K, Stampfer MJ, Ma J, Mucci LA. Genetic variation in RNASEL associated with prostate cancer risk and progression. *Carcinogenesis*. 2010 Sep;31(9):1597-603. doi: 10.1093/carcin/bgq132.
256. Vasuri F, Capizzi E, Bellavista E, Mishto M, Santoro A, **Fiorentino M**, Capri M, Cescon M, Grazi GL, Grigioni WF, D'Errico-Grigioni A, Franceschi C. Studies on immunoproteasome in human liver. Part I: absence in

fetuses, presence in normal subjects, and increased levels in chronic active hepatitis and cirrhosis. *Biochem Biophys Res Commun*. 2010 Jun 25;397(2):301-6. doi: 10.1016/j.bbrc.2010.05.104.

257. Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, **Fiorentino M**, Ligon AH, Pan BS, Richon V, Minna JD, Gazdar AF, Draetta G, Bosari S, Chirieac LR, Lutterbach B, Loda M. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. *Am J Pathol*. 2010 Jul;177(1):415-23. doi: 10.2353/ajpath.2010.090863.
258. **Fiorentino M**, Judson G, Penney K, Flavin R, Stark J, Fiore C, Fall K, Martin N, Ma J, Sinnott J, Giovannucci E, Stampfer M, Sesso HD, Kantoff PW, Finn S, Loda M, Mucci L. Immunohistochemical expression of BRCA1 and lethal prostate cancer. *Cancer Res*. 2010 Apr 15;70(8):3136-9. doi: 10.1158/0008-5472.CAN-09-4100.
259. Priolo C, Agostini M, Vena N, Ligon AH, **Fiorentino M**, Shin E, Farsetti A, Pontecorvi A, Sicinska E, Loda M. Establishment and genomic characterization of mouse xenografts of human primary prostate tumors. *Am J Pathol*. 2010 Apr;176(4):1901-13. doi: 10.2353/ajpath.2010.090873.
260. **Fiorentino M**, Capizzi E, Loda M. Blood and tissue biomarkers in prostate cancer: state of the art. *Urol Clin North Am*. 2010 Feb;37(1):131-41, Table of Contents. doi: 10.1016/j.ucl.2009.11.006.
261. **Fiorentino M**, Vasuri F, Ravaioli M, Ridolfi L, Grigioni WF, Pinna AD, D'Errico-Grigioni A. Predictive value of frozen-section analysis in the histological assessment of steatosis before liver transplantation. *Liver Transpl*. 2009 Dec;15(12):1821-5. doi: 10.1002/lt.21948.
262. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, **Fiorentino M**, Rubin MA, Polyak K, Chan J, Wang Y, Fletcher JA, Santagata S, Corso G, Roviello F, Shivdasani R, Kieran MW, Ligon KL, Stiles CD, Hahn WC, Meyerson ML, Garraway LA. Profiling critical cancer gene mutations in clinical tumor samples. *PLoS One*. 2009 Nov 18;4(11):e7887. doi: 10.1371/journal.pone.0007887.
263. Gruppioni E, Vasuri F, **Fiorentino M**, Capizzi E, Altimari A, Pirini MG, Grazi GL, Malvi D, Grigioni WF, D'Errico-Grigioni A. Real-time quantitative assay for routine testing of HCV RNA in formalin-fixed, paraffin-embedded liver samples. *Diagn Mol Pathol*. 2009 Dec;18(4):232-8. doi:10.1097/PDM.0b013e3181916e31.
264. Flores LM, Kindelberger DW, Ligon AH, Capelletti M, **Fiorentino M**, Loda M, Cibas ES, Jänne PA, Krop IE. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. *Br J Cancer*. 2010 May 11;102(10):1495-502. doi: 10.1038/sj.bjc.6605676.
265. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhir R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, **Fiorentino M**, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. *Cell*. 2009 Jul 23;138(2):245-56. doi: 10.1016/j.cell.2009.04.056.
266. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, **Fiorentino M**, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? *J Clin Oncol*. 2009 Jul 20;27(21):3459-64. doi: 10.1200/JCO.2008.20.4669.
267. Migita T, Ruiz S, Fornari A, **Fiorentino M**, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, Loda M. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. *J Natl Cancer Inst*. 2009 Apr 1;101(7):519-32. doi: 10.1093/jnci/djp030.
268. Nardella C, Carracedo A, Alimonti A, Hobbs RM, Clohessy JG, Chen Z, Egia A, Fornari A, **Fiorentino M**, Loda M, Kozma SC, Thomas G, Cordon-Cardo C, Pandolfi PP. Differential requirement of mTOR in postmitotic tissues and tumorigenesis. *Sci Signal*. 2009 Jan 27;2(55):ra2. doi: 10.1126/scisignal.2000189.

269. Dhillon PK, Barry M, Stampfer MJ, Perner S, **Fiorentino M**, Fornari A, Ma J, Fleet J, Kurth T, Rubin MA, Mucci LA. Aberrant cytoplasmic expression of p63 and prostate cancer mortality. *Cancer Epidemiol Biomarkers Prev.* 2009 Feb;18(2):595-600. doi: 10.1158/1055-9965.EPI-08-0785.
270. Ravaioli M, Grazi GL, Cescon M, Cucchetti A, Ercolani G, **Fiorentino M**, Panzini I, Vivarelli M, Ramacciato G, Del Gaudio M, Vetrone G, Zanello M, Dazzi A, Zanfi C, Di Gioia P, Bertuzzo V, Lauro A, Morelli C, Pinna AD. Liver transplantations with donors aged 60 years and above: the low liver damage strategy. *Transpl Int.* 2009 Apr;22(4):423-33. doi: 10.1111/j.1432-2277.2008.00812.x.
271. **Fiorentino M**, Zadra G, Palescandolo E, Fedele G, Bailey D, Fiore C, Nguyen PL, Migita T, Zamponi R, Di Vizio D, Priolo C, Sharma C, Xie W, Hemler ME, Mucci L, Giovannucci E, Finn S, Loda M. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. *Lab Invest.* 2008 Dec;88(12):1340-8. doi:10.1038/labinvest.2008.97.
272. Altimari A, Gruppioni E, Capizzi E, Bagni A, Corti B, **Fiorentino M**, Lazzarotto T, Lauro A, Pinna AD, Ridolfi L, Grigioni WF, D'errico-Grigioni A. Blood monitoring of granzyme B and perforin expression after intestinal transplantation: considerations on clinical relevance. *Transplantation.* 2008 Jun 27;85(12):1778-83. doi: 10.1097/TP.0b013e318177dfe4.
273. Zucchini N, **Fiorentino M**, D'Errico Grigioni A, Rizzato L, Venettoni S, Nanni Costa A, Grigioni WF; Italian Transplant Research Network. The Italian multiorgan donor cancer screening protocol: 2002-2005 experience. *Transplantation.* 2008 Apr 27;85(8 Suppl):S57-60. doi: 10.1097/TP.0b013e31816c2d42.
274. Altimari A, Grigioni AD, Benedettini E, Gabusi E, Schiavina R, Martinelli A, Morselli-Labate AM, Martorana G, Grigioni WF, **Fiorentino M**. Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. *Am J Clin Pathol.* 2008 May;129(5):756-62. doi: 10.1309/DBPX1MFNDDBW1FL.
275. Capizzi E, Gruppioni E, Grigioni AD, Gabusi E, Grassigli A, Grigioni WF, **Fiorentino M**. Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: a comparative study with FISH, SISH, and immunohistochemistry. *Diagn Mol Pathol.* 2008 Dec;17(4):220-6. doi: 10.1097/PDM.0b013e318161f993.
276. D'Errico-Grigioni A, **Fiorentino M**, Vasuri F, Gruppioni E, Fabbriozio B, Zucchini N, Ballardini G, Morelli C, Pinna AD, Grigioni WF. Tissue hepatitis C virus RNA quantification and protein expression help identify early hepatitis C virus recurrence after liver transplantation. *Liver Transpl.* 2008 Mar;14(3):313-20. doi: 10.1002/lt.21375.
277. Capizzi E, Gabusi E, Grigioni AD, De Iaco P, Rosati M, Zamagni C, **Fiorentino M**. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer. *Diagn Mol Pathol.* 2008 Mar;17(1):34-8. doi: 10.1097/PDM.0b013e3181359e1f.
278. Gruppioni E, Corti B, Altimari A, Gabusi E, Panza E, Grazi GL, Pinna AD, De Ruvo N, **Fiorentino M**, Grigioni WF, Grigioni AD. Application of a fluorescent PCR method for molecular diagnosis of posttransplant lymphoproliferative disorders on routine tissue sections. *Diagn Mol Pathol.* 2005 Sep;14(3):170-6. doi: 10.1097/01.pas.0000162756.84026.44.
279. Lammers KM, Vergopoulos A, Babel N, Gionchetti P, Rizzello F, Morselli C, Caramelli E, **Fiorentino M**, d'Errico A, Volk HD, Campieri M. Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression. *Inflamm Bowel Dis.* 2005 May;11(5):447-54. doi: 10.1097/01.mpa.0000160302.40931.7b.
280. Altimari A, Gruppioni E, **Fiorentino M**, Petraroli R, Pinna AD, Petropulacos K, Ridolfi L, Costa AN, Grigioni WF, Grigioni AD. Genomic allelotyping for distinction of recurrent and de novo hepatocellular carcinoma after orthotopic liver transplantation. *Diagn Mol Pathol.* 2005 Mar;14(1):34-8. doi: 10.1097/01.pas.0000143609.85487.36.
281. Ravaioli M, Grazi GL, Ercolani G, **Fiorentino M**, Cescon M, Golfieri R, Trevisani F, Grigioni WF, Bolondi L, Pinna AD. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. *Transplantation.* 2004 Dec 27;78(12):1780-6. doi: 10.1097/01.tp.0000145892.97114.ee.

282. D'Errico Grigioni A, Corti B, **Fiorentino M**, Pirini MG, Ridolfi L, Venturoli N, Grigioni WF; Italian Emilia-Romagna Region experience. A histopathologic screening method for rational use of organs from prostate-specific antigen- positive multiorgan donors: the Italian Emilia-Romagna Region experience. *Transplantation*. 2004 Sep 27;78(6):941-4. doi: 10.1097/01.tp.0000136989.87896.a4.
283. D'Errico-Grigioni A, **Fiorentino M**, Vasuri F, Corti B, Ridolfi L, Grigioni WF; Pathology Unit for organ safety of the F. Addarii Institute, Bologna; Bagni A, Pirini MG, Malvi D, Fabbri B, Caprara G, Alvaro N. Expanding the criteria of organ procurement from donors with prostate cancer: the application of the new Italian guidelines. *Am J Transplant*. 2010 Aug;10(8):1907-11. doi: 10.1111/j.1600-6143.2010.03198.x.
284. Gouysse G, Frachon S, Hervieu V, **Fiorentino M**, d'Errico A, Dumortier J, Boillot O, Partensky C, Grigioni WF, Scoazec JY. Endothelial cell differentiation in hepatocellular adenomas: implications for histopathological diagnosis. *J Hepatol*. 2004 Aug;41(2):259-66. doi: 10.1016/j.jhep.2004.04.014.
285. **Fiorentino M**, Altimari A, Ravaioli M, Gruppioni E, Gabusi E, Corti B, Vivarelli M, Bringuier PP, Scoazec JY, Grigioni WF, D'Errico-Grigioni A. Predictive value of biological markers for hepatocellular carcinoma patients treated with orthotopic liver transplantation. *Clin Cancer Res*. 2004 Mar 1;10(5):1789-95. doi: 10.1158/1078-0432.
286. D'Errico A, Grassigli A, Gruppioni E, **Fiorentino M**, Corti B, Gabusi E, Morselli-Labate AM, Grigioni WF. Thorough intraoperative analysis of breast sentinel lymph node biopsies: histologic and immunohistochemical findings. *Surgery*. 2004 Mar;135(3):248-54; discussion 255-7, 357. doi: 10.1016/j.surg.2003.10.002.
287. **Fiorentino M**, D'Errico A, Corti B, Casanova S, Ridolfi L, Venturoli N, Sestigiani E, Grigioni WF. A multiorgan donor cancer screening protocol: the Italian Emilia-Romagna region experience. *Transplantation*. 2003 Dec 27;76(12):1695-9. doi: 10.1097/01.TP.0000092306.29395.96.
288. Dall'Olio F, Chiricolo M, D'Errico A, Gruppioni E, Altimari A, **Fiorentino M**, Grigioni WF. Expression of beta-galactoside alpha2,6 sialyltransferase and of alpha2,6-sialylated glycoconjugates in normal human liver, hepatocarcinoma, and cirrhosis. *Glycobiology*. 2004 Jan;14(1):39-49. doi: 10.1093/glycob/cwh002.
289. Nejari M, Hafdi Z, Gouysse G, **Fiorentino M**, Béatrix O, Dumortier J, Pourreyron C, Barozzi C, D'errico A, Grigioni WF, Scoazec JY. Expression, regulation, and function of alpha V integrins in hepatocellular carcinoma: an in vivo and in vitro study. *Hepatology*. 2002 Aug;36(2):418-26. doi: 10.1053/jhep.2002.34611.
290. Corti B, D'Errico A, Pierangeli F, **Fiorentino M**, Altimari A, Grigioni WF. Primary paraganglioma strictly confined to the liver and mimicking hepatocellular carcinoma: an immunohistochemical and in situ hybridization study. *Am J Surg Pathol*. 2002 Jul;26(7):945-9. doi: 10.1097/0000478-200207000-00015.
291. Farinati F, Cardin R, **Fiorentino M**. Apoptosis in alcoholic hepatitis. *J Hepatol*. 2002 Apr;36(4):570-1. doi: 10.1016/s0168-8278(02)00005-3.
292. Cardin R, D'Errico A, **Fiorentino M**, Cecchetto A, Naccarato R, Farinati F. Hepatocyte proliferation and apoptosis in relation to oxidative damage in alcohol-related liver disease. *Alcohol Alcohol*. 2002 Jan-Feb;37(1):43-8. doi: 10.1093/alcalc/37.1.43.
293. Stella F, Davoli F, Brandolini J, Dolci G, Sellitri F, **Fiorentino M**, Bini A. A rare case of giant cystic chondroid hamartoma of the lung presenting with left side pneumothorax. *Minerva Chir*. 2009 Feb;64(1):117-9.
294. Corti B, Altimari A, Gabusi E, Pinna AD, Gruppioni E, Lauro A, Pirini MG, **Fiorentino M**, Ridolfi L, Grigioni WF, Grigioni AD. Two years' experience of acute rejection monitoring of intestinal transplant recipients by real-time PCR assessment of granzyme B and perforin up-regulation: considerations on diagnostic accuracy. *Transplant Proc*. 2006 Jul-Aug;38(6):1726-7. doi: 10.1016/j.transproceed.2006.05.013.
295. Gardini A, Corti B, **Fiorentino M**, Altimari A, Ercolani G, Grazi GL, Pinna AD, Grigioni WF, D'Errico Grigioni A. Expression of connective tissue growth factor is a prognostic marker for patients with intrahepatic cholangiocarcinoma. *Dig Liver Dis*. 2005 Apr;37(4):269-74. doi: 10.1016/j.dld.2004.11.001.

296. Corti B, Altimari A, Gabusi E, Pinna AD, Lauro A, Morselli-Labate AM, Gruppioni E, Pirini MG, **Fiorentino M**, Ridolfi L, Grigioni WF, D'Errico-Grigioni A. Potential of real-time PCR assessment of granzyme B and perforin up-regulation for rejection monitoring in intestinal transplant recipients. *Transplant Proc.* 2005 Dec;37(10):4467-71. doi: 10.1016/j.transproceed.2005.11.035.
297. D'Errico A, Corti B, **Fiorentino M**, Di Simone M, Mattioli S, Grigioni WF. Endoscopic finding of granular cell tumour associated with leiomyomas in the oesophagus. *Dig Liver Dis.* 2004 Apr;36(4):292-5. doi: 10.1016/j.dld.2003.09.022.
298. **Fiorentino M**, Altimari A, Ravaioli M, Gruppioni E, Gabusi E, Corti B, Vivarelli M, Bringuier PP, Scoazec JY, Grigioni WF, D'Errico-Grigioni A. Predictive value of biological markers for hepatocellular carcinoma patients treated with orthotopic liver transplantation. *Clin Cancer Res.* 2004 Mar 1;10(5):1789-95. doi: 10.1158/1078-0432.ccr-1149-3.
299. Altimari A, **Fiorentino M**, Gabusi E, Gruppioni E, Corti B, D'Errico A, Grigioni WF. Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. *Dig Liver Dis.* 2003 May;35(5):332-8. doi: 10.1016/s1590-8658(03)00077-x.
300. D'Errico A, Corti B, Pinna AD, Altimari A, Gruppioni E, Gabusi E, **Fiorentino M**, Bagni A, Grigioni WF. Granzyme B and perforin as predictive markers for acute rejection in human intestinal transplantation. *Transplant Proc.* 2003 Dec;35(8):3061-5. doi: 10.1016/j.transproceed.2003.10.073.
301. Gabusi E, Lattes C, **Fiorentino M**, D'Errico A, Grigioni WF. Expression of Epstein-Barr virus-encoded RNA and biological markers in Italian nasopharyngeal carcinomas. *J Exp Clin Cancer Res.* 2001 Sep;20(3):371-6.
302. **Fiorentino M**, Altimari A, D'Errico A, Gabusi E, Chieco P, Masetti M, Grigioni WF. Low p27 expression is an independent predictor of survival for patients with either hilar or peripheral intrahepatic cholangiocarcinoma. *Clin Cancer Res.* 2001 Dec;7(12):3994-9.
303. Farinati F, Cardin R, **Fiorentino M**, D'errico A, Grigioni W, Cecchetto A, Naccarato R. Imbalance between cytoproliferation and apoptosis in hepatitis C virus related chronic liver disease. *J Viral Hepat.* 2001 Jan;8(1):34-40. doi: 10.1046/j.1365-2893.2001.00267.x.
304. **Fiorentino M**, Altimari A, D'Errico A, Cukor B, Barozzi C, Loda M, Grigioni WF. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. *Clin Cancer Res.* 2000 Oct;6(10):3966-72.
305. Pellicano R, Leone N, Berrutti M, Cutufia MA, **Fiorentino M**, Rizzetto M, Ponzetto A. Helicobacter pylori seroprevalence in hepatitis C virus positive patients with cirrhosis. *J Hepatol.* 2000 Oct;33(4):648-50. doi: 10.1034/j.1600-0641.2000.033004648.x.
306. Leone N, Volpes R, Carrera M, Pellicano R, De Paolis P, **Fiorentino M**, Fronda GR, Rizzetto M. Hepatocellular carcinoma in a non-cirrhotic liver. Two case reports and literature review. *Panminerva Med.* 2000 Jun;42(2):151-4.
307. D'Errico A, Barozzi C, **Fiorentino M**, Carella R, Di Simone M, Ferruzzi L, Mattioli S, Grigioni WF. Role and new perspectives of transforming growth factor-alpha (TGF-alpha) in adenocarcinoma of the gastro-oesophageal junction. *Br J Cancer.* 2000 Feb;82(4):865-70. doi: 10.1054/bjoc.1999.1013.
308. **Fiorentino M**, D'Errico A, Altimari A, Barozzi C, Grigioni WF. High levels of BCL-2 messenger RNA detected by in situ hybridization in human hepatocellular and cholangiocellular carcinomas. *Diagn Mol Pathol.* 1999 Dec;8(4):189-94. doi: 10.1097/00019606-199912000-00004.
309. **Fiorentino M**, D'Errico A, Barozzi C, Grigioni WF. Discrepancies between detection of Bcl-2 by in situ hybridization and immunocytochemistry in human prostate cancer tissues. *Int J Cancer.* 1998 Dec 18;79(6):614-8. doi: 10.1002/(sici)1097-0215(19981218)79:6<614::aid-ijc10>3.0.co;2-i.
310. D'Errico A, Deleonardi G, **Fiorentino M**, Scoazec JY, Grigioni WF. Diagnostic implications of albumin messenger RNA detection and cytokeratin pattern in benign hepatic lesions and biliary cystadenocarcinoma. *Diagn Mol Pathol.* 1998 Dec;7(6):289-94. doi: 10.1097/00019606-199812000-00001.

311. Posner MR, Johnston PG, Tishler RB, Andersen J, **Fiorentino M**, Busse PM, Cavacini LA, Colevas AD, Clark J, Norris CM. The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck. *Oncologist*. 1998;3(6):424-431.
312. Lise M, Loda M, **Fiorentino M**, Mercurio AM, Summerhayes IC, Lavin PT, Jessup JM. Association between sucrase-isomaltase and p53 expression in colorectal cancer. *Ann Surg Oncol*. 1997 Mar;4(2):176-83. doi: 10.1007/BF02303802.
313. Loda M, Cukor B, Tam SW, Lavin P, **Fiorentino M**, Draetta GF, Jessup JM, Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. *Nat Med*. 1997 Feb;3(2):231-4. doi: 10.1038/nm0297-231.
314. Magi-Galluzzi C, Mishra R, **Fiorentino M**, Montironi R, Yao H, Capodieci P, Wishnow K, Kaplan I, Stork PJ, Loda M. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. *Lab Invest*. 1997 Jan;76(1):37-51.
315. Grazi GL, Gallucci A, Masetti M, Jovine E, **Fiorentino M**, Mazziotti A, Gozzetti G. Surgical therapy for undifferentiated (embryonal) sarcomas of the liver in adults. *Am Surg*. 1996 Nov;62(11):901-6.
316. D'Errico A, **Fiorentino M**, Ponzetto A, Daikuhara Y, Tsubouchi H, Brechot C, Scoazec JY, Grigioni WF. Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: its specific receptor c-met does. *Hepatology*. 1996 Jul;24(1):60-4. doi: 10.1002/hep.510240112.
317. Scoazec JY, Flejou JF, D'Errico A, **Fiorentino M**, Zamparelli A, Bringuier AF, Feldmann G, Grigioni WF. Fibrolamellar carcinoma of the liver: composition of the extracellular matrix and expression of cell-matrix and cell-cell adhesion molecules. *Hepatology*. 1996 Nov;24(5):1128-36. doi: 10.1002/hep.510240525.
318. Racine-Samson L, Scoazec JY, D'Errico A, **Fiorentino M**, Christa L, Moreau A, Roda C, Grigioni WF, Feldman G. The metabolic organization of the adult human liver: a comparative study of normal, fibrotic, and cirrhotic liver tissue. *Hepatology*. 1996 Jul;24(1):104-13. doi: 10.1002/hep.510240118.
319. D'Errico A, Baccarini P, **Fiorentino M**, Ceccarelli C, Bonazzi C, Ponzetto A, Scoazec JY, Mancini AM, Grigioni WF. Histogenesis of primary liver carcinomas: strengths and weaknesses of cytokeratin profile and albumin mRNA detection. *Hum Pathol*. 1996 Jun;27(6):599-604. doi: 10.1016/s0046-8177(96)90169-0.
320. Kozyraki R, Scoazec JY, Flejou JF, D'Errico A, Bedossa P, Terris B, **Fiorentino M**, Bringuier AF, Grigioni WF, Feldmann G. Expression of cadherins and alpha-catenin in primary epithelial tumors of the liver. *Gastroenterology*. 1996 Apr;110(4):1137-49. doi: 10.1053/gast.1996.v110.pm8613003.
321. Scoazec JY, Flejou JF, D'Errico A, Couvelard A, Kozyraki R, **Fiorentino M**, Grigioni WF, Feldmann G. Focal nodular hyperplasia of the liver: composition of the extracellular matrix and expression of cell-cell and cell-matrix adhesion molecules. *Hum Pathol*. 1995 Oct;26(10):1114-25. doi: 10.1016/0046-8177(95)90274-0.
322. D'Errico A, Grigioni WF, **Fiorentino M**, Baccarini P, Grazi GL, Mancini AM. Overexpression of p53 protein and Ki67 proliferative index in hepatocellular carcinoma: an immunohistochemical study on 109 Italian patients. *Pathol Int*. 1994 Sep;44(9):682-7. doi: 10.1111/j.1440-1827.1994.tb02947.x.
323. **Fiorentino M**, Grigioni WF, Baccarini P, D'Errico A, De Mitri MS, Pisi E, Mancini AM. Different in situ expression of insulin-like growth factor type II in hepatocellular carcinoma. An in situ hybridization and immunohistochemical study. *Diagn Mol Pathol*. 1994 Mar;3(1):59-65. doi: 10.1097/00019606-199403010-00010.
324. D'Errico A, Grigioni WF, **Fiorentino M**, Baccarini P, Lamas E, De Mitri S, Gozzetti G, Mancini AM, Brechot C. Expression of insulin-like growth factor II (IGF-II) in human hepatocellular carcinomas: an immunohistochemical study. *Pathol Int*. 1994 Feb;44(2):131-7. doi: 10.1111/j.1440-1827.1994.tb01697.x.
325. Grigioni WF, D'Errico A, Fortunato C, **Fiorentino M**, Mancini AM, Stetler-Stevenson WG, Sobel ME, Liotta LA, Onisto M, Garbisa S. Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. *Mod Pathol*. 1994 Feb;7(2):220-5.

326. Baccarini P, **Fiorentino M**, D'Errico A, Mancini AM, Grigioni WF. Detection of anti-sense transcripts of the insulin-like growth factor-2 gene in Wilms' tumor. Am J Pathol. 1993 Dec;143(6):1535-42.

Lettere

- Mengoli MC, Bertolini F, Tiseo M, Barbieri F, **Fiorentino M**, Ardizzoni A, Rossi G. MET DNA Alterations in NSCLC-Letter. Clin Cancer Res. 2016 Jul 15;22(14):3697-8. doi: 10.1158/1078-0432.CCR-16-0351.
- Gelsomino F, **Fiorentino M**, Zompatori M, Poerio A, Melotti B, Sperandi F, Gargiulo M, Borghi C, Ardizzoni A. Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques? Ann Oncol. 2018 Jan 1;29(1):284-286. doi: 10.1093/annonc/mdx718.

Capitoli di testi

- Seyed Mohammad Kazem Aghamir, Fatemeh Khatami, Vahid Abedi Yarandi, AhmadReza Rezaeian, **Michelangelo Fiorentino**. Chapter 2 - Overview of liquid biopsy. In: Editor(s) Seyed Mohammad Kazem Aghamir Liquid Biopsy in Urogenital Cancers and its Clinical Utility. Academic Press, 2022, Pages 5-30, ISBN 9780323998840
- Giunchi, F., Vasuri, F., **Fiorentino, M.** (2017). Epidemiology of Hepatocellular Carcinoma. In: Loda, M., Mucci, L., Mittelstadt, M., Van Hemelrijck, M., Cotter, M. (eds) Pathology and Epidemiology of Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-35153-7_23
- Vasuri, F., Giunchi, F., **Fiorentino, M.** (2017). The Pathology and Molecular Pathology of Hepatocellular Carcinoma. In: Loda, M., Mucci, L., Mittelstadt, M., Van Hemelrijck, M., Cotter, M. (eds) Pathology and Epidemiology of Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-35153-7_24
- Benedettini E, Penney K, **Fiorentino M**, Loda M. Recent Advances in Prostate Cancer. In TUMOR BIOLOGY. 2011WORLD SCIENTIFIC. Doi:10.1142/9789814329460_0006

Traduzioni di testi

- RUBIN'S PATHOLOGY: Clinicopathologic Foundations of Medicine, di Emanuel Rubin et al., 4th edition 2005 Lippincott Williams& Wilkins, USA. Edizione Italiana a cura di Anna Gasperi-Campani e Walter F. Grigioni / Gasperi Campani, Anna; **Fiorentino, Michelangelo**; Corti, Barbara; D'Errico, Antonietta; Capelli, A.; Iannaccone, M.. - STAMPA. - (2006), pp. 1-1597.

h-index:53 according to Scopus (11054 citazioni)

Attività Istituzionali

- Coordinatore I semestre IV anno C.d.L. Medicine and Surgery
 - AA.AA 2021/22; 2022/23; 2023/24; 2024/25
 - Università di Bologna
- Membro Commissione Tecnico Pedagogica C.d.L. Medicine and Surgery
 - AA.AA 2021/22; 2022/23; 2023/24; 2024/25
 - Università di Bologna
- Membro della commissione per il Bando Erasmus+ tirocinio

- AA.AA2022/23; 2023/24; 2024/25
- Università di Bologna
- Membro della Commissione Paritetica per lo svolgimento del tirocinio post lauream per l'abilitazione alla professione di medico-chirurgo ex DM 445/2001
 - AA.AA2019/20; 2020/21; 2021/22; 2022/23
 - Università di Bologna
- Membro del Collegio di Dottorato in "SCIENZE CARDIO NEFRO TORACICHE"
 - AA.AA 2017/18; 2018/19; 2019/20; 2020/21; 2021/22; 2022/23; 2023/2024
 - Università di Bologna
- Membro del Coordinamento Regionale della rete Oncologica ed Emato – Oncologica
 - 2023-
 - Regione Emilia-Romagna
- Coordinatore del Gruppo di Lavoro per la Diagnostica Avanzata. Coordinamento Regionale delle Reti Oncologiche
 - 2021-2022
 - Regione Emilia-Romagna
- Estensore delle Linee Guida nazionali per il Carcinoma della Prostata
 - 2020-2021
 - Associazione Italiana Oncologia Medica (AIOM)
- Membro della commissione Oncologia dell'Emilia-Romagna
 - 2012-2015
 - Regione Emilia Romagna
- Referente esperto della Regione Emilia-Romagna nel gruppo di lavoro sull'aggiornamento delle prestazioni di assistenza specialistica ambulatoriale
 - 2014
 - Ministero della Salute

Attività didattica frontale

- 84400 - IMMUNE, RHEUMATIC, AND SKIN DISEASES (I.C.) - IMMUNE, RHEUMATIC AND SKIN PATHOLOGY
 - AA.AA 2021/22; 2022/23; 2023/24; 2024/25
 - Ore8; 1 CFU

- SSD MEDS-04/A ex-MED/08
- Lingua Inglese
- Università di Bologna, C.d.L. Medicine and Surgery, Laurea Magistrale a ciclo unico
- 84467 - ABDOMINAL DISEASES (I.C.) - ABDOMINAL PATHOLOGY
 - AA.AA2020/21; 2021/22; 2022/23; 2023/24; 2024/25
 - Ore 16; 2 CFU
 - SSD MEDS-04/A ex-MED/08
 - Lingua Inglese
 - Università di Bologna, C.d.L. Medicine and Surgery, Laurea Magistrale a ciclo unico
- 84420 - BONE AND JOINT DISEASES (I.C.) - BONE AND JOINT PATHOLOGY
 - AA.AA 2020/21; 2021/22; 2022/23; 2023/24; 2024/25
 - Ore 8; 1 CFU
 - SSD MEDS-04/A ex-MED/08
 - Lingua Inglese
 - Università di Bologna, C.d.L. Medicine and Surgery, Laurea Magistrale a ciclo unico
- 00031 - ANATOMIA PATOLOGICA (C.I.) - ANATOMIA PATOLOGICA - A-K - AK-B
 - A.A. 2024/25
 - Ore 10; 10 CFU
 - SSD MEDS-04/A ex-MED/08
 - Lingua Italiano
 - Università di Bologna, C.d.L. Medicinae Chirurgia, Laurea Magistrale a ciclo unico
- 00031 - ANATOMIA PATOLOGICA (C.I.) - ANATOMIA PATOLOGICA - L-Z - LZ-F
 - A.A. 2024/25
 - Ore 10; 10 CFU
 - SSD MEDS-04/A ex-MED/08
 - Lingua Italiano
 - Università di Bologna, C.d.L. Medicinae Chirurgia, Laurea Magistrale a ciclo unico
- 65630 - DIAGNOSTIC TECHNOLOGY (I.C.) - CLINICAL PATHOLOGY - 2 Modulo 2
 - AA.AA2019/20

- Ore 8; 1 CFU
- SSD MEDS-02/B ex-MED/05
- Lingua Inglese
- Università di Bologna, C.d.L. Medicine and Surgery, Laurea Magistrale a ciclo unico
- 24021 - ANATOMIA PATOLOGICA I (C.I.) - ISTOPATOLOGIA GENERALE
 - AA.AA 2020/21; 2021/22; 2022/23; 2023/24; 2024/25
 - Ore 24; 2 CFU
 - SSD MEDS-04/A ex-MED/08
 - Lingua Italiana
 - Università di Bologna, C.d.L. Tecniche di Laboratorio Biomedico (Abilitante alla Professione Sanitaria di Tecnico di Laboratorio Biomedico)
- 93307 - PATOLOGIA MOLECOLARE E DIAGNOSTICA
 - AA.AA 2020/21; 2021/22; 2022/23
 - Ore 48; 6 CFU
 - SSD MEDS-04/A ex-MED/08
 - Lingua Italiana
 - Università di Bologna, C.d.L. Biotecnologie
- 93307 - PATOLOGIA MOLECOLARE E DIAGNOSTICA, Modulo 1
 - 2023/24; 2024/25
 - Ore 32; 4 CFU
 - SSD MEDS-04/A ex-MED/08
 - Lingua Italiana
 - Università di Bologna, C.d.L. Biotecnologie
- 86869 - PATOLOGIA MOLECOLARE E DIAGNOSTICA
 - AA.AA2017/18; 2018/19; 2019/2020 /21
 - Ore 48; 6 CFU
 - SSD MEDS-02/B ex-MED/05
 - Lingua Italiana
 - Università di Bologna, C.d.L. Biotecnologie
- 61682 - DIAGNOSTICA MOLECOLARE
 - AA.AA2016/17

- Ore 48; 6 CFU
- SSD MEDS-04/A ex-MED/08
- Lingua Italiana
- Università di Bologna, C.d.L. Biotecnologie
- 57176 - PATOLOGIA CLINICA II (C.I.) - PATOLOGIA CLINICA APPLICATA
 - AA.AA2017/18; 2018/2019; 2019/2020
 - Ore 24; 2 CFU
 - SSD MEDS-02/B ex-MED/05
 - Lingua Italiana
 - Università di Bologna, C.d.L. Tecniche di Laboratorio Biomedico (Abilitante alla Professione Sanitaria di Tecnico di Laboratorio Biomedico)
- 76048 - PATOLOGIA C.I. - PATOLOGIA CLINICA
 - AA.AA 2018/2019; 2019/2020
 - Ore 8; 1 CFU
 - SSD MEDS-02/B ex-MED/05
 - Lingua Italiana
 - Università di Bologna, C.d.L. Podologia (Abilitante alla Professione Sanitaria di Podologo)
- 07732 - DIAGNOSTICA DI LABORATORIO (C.I.) - PATOLOGIA CLINICA - 2 Modulo 2
 - AA.AA2018/19; 2019/20
 - Ore 16; 5 CFU
 - SSD MEDS-02/B ex-MED/05
 - Lingua Italiana
 - Università di Bologna, C.d.L. Magistrale in Biotecnologie Mediche
- 57397 - ANATOMIA PATOLOGICA I (C.I.) - TECNICHE DI ISTOPATOLOGIA (a contratto)
 - AA.AA2012/13; 2013/14; 2014/15; 2015/16; 2016/17
 - Ore 24; 2 CFU
 - SSD MEDS-04/A ex-MED/08
 - Lingua Italiana
 - Università di Bologna, C.d.L. Tecniche di Laboratorio Biomedico (Abilitante alla Professione Sanitaria di Tecnico di Laboratorio Biomedico)
- 12946 - ATTIVITA' DI BASE (C.I.) - BIOLOGIA MOLECOLARE

- AA.AA 2014/15; 2015/16; 2016/17; 2017/18; 2018/19; 2019/20; 2020/21; 2021/22; 2022/23; 2023/24
 - Ore 8; 1 CFU
 - SSD BIOS-08/A ex-BIO/11
 - Lingua Italiana
 - Università di Bologna, Scuola di Specializzazione in Radioterapia
- 79997 - ATTIVITA' DI BASE (C.I.) - ANATOMIA PATOLOGICA
 - AA.AA 2019/20; 2020/21; 2021/22; 2022/23; 2023/24
 - Ore 8; 1 CFU
 - SSD MEDS-04/A ex-MED/08
 - Lingua Italiana
 - Università di Bologna, Scuola di Specializzazione in Urologia
- 39902 - CORSO INTEGRATO AREA CLINICA COMUNE SPECIALISTICA V - ANATOMIA PATOLOGICA 5 (a contratto)
 - AA.AA 2014/15; 2015/16; 2016/17; 2017/18
 - Ore 8; 1 CFU
 - SSD MEDS-04/A ex-MED/08
 - Lingua Italiana
 - Università di Bologna, Scuola di Specializzazione in Urologia
- 39888 - CORSO INTEGRATO AREA CLINICA COMUNE SPECIALISTICA IV - ANATOMIA PATOLOGICA 4 (a contratto)
 - AA.AA 2014/15; 2015/16; 2016/17
 - Ore 8; 1 CFU
 - SSD MEDS-04/A ex-MED/08
 - Lingua Italiana
 - Università di Bologna, Scuola di Specializzazione in Urologia
- 80275 - ANATOMIA PATOLOGICA III - DIDATTICA FRONTALE - 2 Modulo 3 b
 - AA.AA 2018/19; 2019/20; 2020/21; 2021/22; 2022/23; 2023/24
 - Ore 16; 7 CFU
 - SSD MEDS-04/A ex-MED/08
 - Lingua Italiana
 - Università di Bologna, Scuola di Specializzazione in Anatomia Patologica

- 80270 - ANATOMIA PATOLOGICA I - DIDATTICA FRONTALE - 2 Modulo 1 B
 - A.A2023/24
 - Ore 8; 7 CFU
 - SSD MEDS-04/A ex-MED/08
 - Lingua Italiana
 - Università di Bologna, Scuola di Specializzazione in Anatomia Patologica
- 39673 - CORSO INTEGRATO AREA CLINICA COMUNE SPECIALISTICA V - PATOLOGIA CLINICA 5
 - AA.AA2017/18
 - Ore 8; 1 CFU
 - SSD MEDS-02/B ex-MED/05
 - Lingua Italiana
 - Università di Bologna, Scuola di Specializzazione in Anatomia Patologica
- 80897 - PATOLOGIA CLINICA E BIOCHIMICA CLINICA IV (C.I) - DIDATTICA FRONTALE - PATOLOGIA CLINICA 4-B - 2 Mod.2
 - AA.AA 2017/18
 - Ore 16; 6 CFU
 - SSD MEDS-02/B ex-MED/05
 - Lingua Italiana
 - Università di Bologna, Scuola di Specializzazione in Patologica Clinica e Biochimica Clinica

Attività didattica frontale svolta all'estero

- EPI 508 – PATHOLOGY FOR EPIDEMIOLOGISTS
 - AA.AA 2010; 2012; 2014; 2016; 2018; 2020; 2022 (even years)
 - Ore 16; 1.25 CFU
 - Lingua iNGLESE
 - HARVARD SCHOOL OF PUBLIC HEALTH, SCHOOL OF EPIDEMIOLOGY, BOSTON, MA, U.S.A.

Attività didattica integrativa

- Relatore di tesi: Totale 31

- **Tesi di laurea a ciclounico in Medicine and Surgery: Totale 8** (A.A. 2022/23 matricole N. 0000854424; 0000853452; 0000851551; 0000854435; A.A. 2023/24 matricole N. 0000891285; 0000902378; 0000902512; 0000902489)
- **Tesi di Laurea Magistrale in Biologia della Salute: Totale 6** (AA 2017/18 matricola N. 0000817215; AA 2020/21 matricola N. 0000942620; AA 2021/22 matricole N. 0000994559; 0000997895; AA 2022/23 matricola N. 0001054866; 2023/2024 matricola N. 0001098945)
- **Tesi di Laurea Magistrale in Biotecnologie Mediche: Totale 1**(AA 2019/20 matricola N. 0000847470)
- **Tesi di Laurea Triennale in Biologia: Totale 5**(AA 2017/2018 matricole N. 0000736463; 0000753310; AA 2018/19 matricola N. 0000753243; AA 2020/2021 matricola N. 0000873390; AA 2022/23 matricola N. 0000904433)
- **Tesi di Laurea triennale in Biotecnologie: Totale 3** (AA 2017/18 matricola N. 0000720453; AA 2022/23 matricola N. 0000975960; AA 2023/24 matricola N. 0001043764)
- **Tesi di Laurea in Tecnico di Laboratorio Biomedico: Totale 5**(AA 2012/13 matricola N. 0000587559; AA 2014/15 matricola N. 0000638312; 2019/20 matricole N. 0000781781; 0000852359; AA 2021/2022 matricola N. 0000941908)
- **Tesi di Specializzazione in Anatomia Patologica: Totale 2**(AA 2018/19 matricola N. 0000747064; AA 2020/21 matricola N. 0000857910)
- **Tesi di Dottorato: Totale 1**(AA 2023/24 Dr. Costantino Ricci)
- **Correlatore di tesi: Totale 2**
 - **Tesi di Laurea Magistrale in Farmacia: Totale 2** (AA 2022/2023 matricola N. 0000830216; AA 2023/24 matricola N. 0000900743)
- **Controrelatore di tesi: Totale 1**
 - **Tesi di Laurea Magistrale in Biotecnologie Mediche: Totale 1** (AA 2019/20 matricola N. 0000844160)
- Tutoraggio di tirocinio elettivo di studenti di Medicina e chirurgia e Medicine and Surgery: **Totale 20**
- Tutoraggio di tirocinio di Laurea di studenti di TSLB: **Totale 5**
- Tutoraggio pluriennale attività' specializzandi in Anatomia Patologica: **Totale 3**

Attività assistenziale

- **2001-2006. AZIENDA OSPEDALIERO-UNIVERSITARIA S.ORSOLA-MALPIGHI . DIRIGENTE MEDICO DI ANATOMIA PATOLOGICA, A TEMPO INDETERMINATO, A TEMPO PIENO. INCARICODIRIGENZIALE PROFESSIONALE.**

- **2007.** AZIENDA OSPEDALIERO-UNIVERSITARIA S.ORSOLA-MALPIGHI . DIRIGENTE MEDICO DI ANATOMIA PATOLOGICA, A TEMPO INDETERMINATO, A TEMPO PIENO. **INCARICO DIRIGENZIALE SPECIALISTICO.**
- **2008.** DANA-FARBER CANCER INSTITUTE, BOSTON, MA U.S.A. **STAFF PATHOLOGIST E ASSOCIATE DIRECTOR** DEL CENTER FOR ONCOLOGIC MOLECULAR PATHOLOGY
- **2008-2017.** AZIENDA OSPEDALIERO-UNIVERSITARIA S.ORSOLA-MALPIGHI. DIRIGENTE MEDICO DI ANATOMIA PATOLOGICA, A TEMPO INDETERMINATO, A TEMPO PIENO. INCARICO DIRIGENZIALE DI **RESPONSABILE DELLA STRUTTURA SEMPLICE (SS)** DENOMINATA “LABORATORIO DI PATOLOGIA MOLECOLARE ONCOLOGICA E DEI TRAPIANTI”
- **2017-2019.** UNIVERSITÀ DI BOLOGNA E AZIENDA OSPEDALIERO-UNIVERSITARIA S.ORSOLA-MALPIGHI. PROFESSORE ASSOCIATO DI PATOLOGIA CLINICA EQUIPARATO A DIRIGENTE MEDICO DI ANATOMIA PATOLOGICA. INCARICO DIRIGENZIALE DI **RESPONSABILE DELLA STRUTTURA SEMPLICE (SS)** DENOMINATA “LABORATORIO DI PATOLOGIA MOLECOLARE ONCOLOGICA E DEI TRAPIANTI”
- **2019 A OGGI.** UNIVERSITÀ DI BOLOGNA E AZIENDA USL DI BOLOGNA. PROFESSORE ASSOCIATO DI ANATOMIA PATOLOGICA EQUIPARATO A DIRIGENTE MEDICO DI ANATOMIA PATOLOGICA, A TEMPO INDETERMINATO, A TEMPO PIENO. INCARICO DIRIGENZIALE DI **DIRETTORE DELLA UNITÀ OPERATIVA COMPLESSA (UOC)** DENOMINATA “ANATOMIA PATOLOGICA OSPEDALE MAGGIORE” DELLA AUSL DI BOLOGNA
- **2001-2024** Primo firmatario di: 40.414 referti istologici/citologici/autoptici/di patologia molecolare

AUTODICHIARAZIONE AI SENSI DEGLI ARTT. 46 E 47 D.P.R. N. 445/2000

IL sottoscritto FIORENTINO MICHELANGELO , nato il 27 . 10 .1967 a BOLOGNA (BO), residente in BOLOGNA (BO), via SANTO STEFANO 92 e domiciliato in BOLOGNA (BO), via SANTO STEFANO 92 identificato a mezzo CARTA DI IDENTITA' nr. CA78731JP rilasciato da MINISTERO DELL'INTERNO COMUNE DI BOLOGNA in data 12 .08 .2021 , utenza telefonica +393387881072 ,

consapevole delle conseguenze penali previste in caso di dichiarazioni mendaci a pubblico ufficiale (art. 495 c.p.)

DICHIARA SOTTO LA PROPRIA RESPONSABILITÀ

- che le informazioni e le dichiarazioni contenute nel presente curriculum vitae corrispondono al vero;
- di essere in possesso di tutti i titoli riportati nel presente curriculum vitae;
- che ogni contenuto relativo a titoli, pubblicazioni e attività svolte riportate nel presente curriculum vitae corrisponde al vero;
- che le copie delle pubblicazioni presentate ai fini della valutazione analitica sono conformi all'originale.

(Luogo e data) Bologna 28/09/2024

Firma

